reason report
initi oncolog op loxo
bottom line initi coverag target oncolog
name op loxo bgne tsro mp
rate bullish
outlook sector think loxo bgne tsro
outperform like under-perform think
like perform in-lin market
stock see outperform market
pt leader target oncolog expect competit
threat subsid gist sm still signific player ret
pt commerci execut stori stronger
expect adcetri adopt front line posit data
could expand label pipelin advanc broaden thesi
loxo pt best class target agent continu drive
valu regulatori clariti emerg ret scienc acumen
bgne pt continu valu advanc pipelin
underappreci parp gastric cancer opportun expect china
becom tangibl valu driver
tsro pt invest thesi broaden beyond zejula ovarian
cancer pipelin emerg
stock see under-perform market
pt emerg profil show drug unlik
competit avapritinib sm pdgfr given unfavor
pk/pd profil earli clinic data assess medacorp
gist would threaten perceiv domin area
compani inform leerink partner llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
stock think perform line
data esmo follow preliminari decis european patent offic
found rubraca novel near-term catalyst oral argument
schedul dec medacorp specialist think opposit
strong argument detail insid report outcom relev
import market like debat see overhang
stock potenti takeout thesi
pt pend fda decis partial clinic hold expect
lift await clariti number key value-driv
program limbo
pt range-bound transform asset emerg
pt promis scienc encourag launch solid
tumor program work unlock stock valu current level
initi target oncolog
initi coverag target oncolog sector biotechnolog stock issu compani
develop drug target number differ solid hematolog malign util rang
technolog core compet
remain bullish sector biotechnolog sector experienc surg capit invest
investor will financ early-stag compani develop drug alter genet driver
diseas well compani improv long-stand technolog like chemotherapi antibody-
drug conjug adc interestingli investor attent driven merger acquisit
histor key driver biotech appreci well support
leerink partner research factset figur million
view stimulu fundament understand scienc drive variou
malign evolv improv target oncolog perspect view
recent enthusiasm top rather begin appli scienc renaiss better
understand genet diseas emerg well drug predict
design
better knowledg diseas process allow investor abil quantifi risk
opportun earlier stage drug develop process result influx capit earlier stage
compani seen previous believ begin cellular therapi genet
engin target therapi like continu chang cours outcom diseas
offer signific opportun investor premis fund like acceler
innov turn acceler fund
leerink partner research factset figur million
leerink partner research factset figur million
winner loser environ think winner go compani
invest wise meaning research develop identifi opportun intervent make
sens work deliv messag investor convers loser like
compani pick viabl therapeut area intervent deliv messag
accur investor believ mani investor digest preclin data dive deeper
genet diseas process make decis compani provid sound scientif
basi program like reward
investor less risk advers less risk shift earlier stage invest result
number ipo offer prior tradit proof-of-concept stage would argu bar
shift proof-of-concept requir less clinic data off-set better understand
diseas predict drug candid result robust valuat mani
compani get valuat asset previous overlook
rise capit market invest earlier stage asset present altern fund sourc recognit
earlier stage asset capit market made difficult larg pharma biotech justifi
necessari acquisit premium find uncaptur valu and/or synergi robust natur ipo
market also given earli stage compani altern fund sourc partner larg pharma
biotech like result unencumb asset advanc clinic eventu
could lead transact albeit higher price seen previous continu see compani
platform possess uncaptur valu potenti acquir especi novel
progress mani diseas termin delay one main benefactor
evolut cancer patient offer drug make cancer non-termin event
believ diseas alter intervent continu evolv bodi knowledg expand
exponenti novel target emerg viabl intervent
high profil failur deflat sector target oncolog perspect one concern investor
take risk earlier stage asset whether high profil failur like contract premium
view see biotech renaiss deflat one failur sever binari
event disappoint result larg shift capit compani result
overal exit sector capit shift invest within biotechnolog view largest
risk sector perform macro-environ signific healthcar drug price reform
rather company-specif event
fli ointment could commerci execut invest thesi start shift one base
exclus de-risk clinic asset one driven commerci execut possibl
develop stage biotechnolog compani fail deliv expect less sector mani
biotech compani may transit sole orient compani commerci
enterpris sell drug well give prudent guidanc investor believ unlik
return ubiquit short launch thesi preval sever year ago possibl sequenc
fail commerci launch could reignit investor skeptic biotech commerci execut
view investor realiz increas payor leverag made difficult gaug overal market demand
reimburs establish appear patient expect initi launch
trajectori similarli mani compani success temper expect launch howev one risk
sector could percept biotech compani fulfil dream commerci
flexibl regulatori environ posit neg think current regulatori shift
author will expedit approv grant broader label accept less data grant
market registr gener signific posit biotechnolog without advers
consequ view regulatori shift help de-risk shorten clinic regulatori
stage drug trade-off increas risk commerci stage obviou impact
lower regulatori bar could make easier new entrant emerg fraction commerci
opportun particularli applic drug get acceler approv pathway
util extens compani develop target oncolog agent importantli fda grant
acceler approv prevent agent pursu similarli expedit pathway
agenc premis without fulli approv drug bar standard-of-car chang
make sens drug could eventu fail confirmatori trial would prudent shift bar
final approv receiv also seen agenc demonstr willing grant broader label
often use knowledg class drug rather exclus molecul specif data present
sponsor case parp inhibitor class astrazeneca/merck abl secur broad
approv lynparza second-lin ovarian cancer mainten despit pivot trial includ
brca patient result signific chang commerci dynam anticip
anoth impact gener regulatori environ less data make harder truli assess
drug safeti efficaci profil drug widespread usag increas risk
new advers event profil emerg like lead cautiou prescrib clinician
especi number safeti issu label revisions/revoc happen consequ
environ hope better understand drug profil diseas process off-set risk
winner loser choos wise fund earlier stage compani without risk
requir deep knowledg biolog tumor diseas treatment paradigm well abil
discern fact fiction environ believ winner like continu outperform
enjoy signific premium compani fail deliv continu see invest dollar
flow earlier stage compani execut valu away compani
deliv execut commun messag effect invest commun
 driven renaiss increas compani robust drug discoveri potenti
invest target histor invest strategi investor often form exit
strategi biotechnolog compani high degre specul regard takeout potenti often
experi signific volatil around news flow increas decreas percept acquisit
news flow rang direct rumor regard transact action taken compani
lessen mind investor prospect near-term event occur financ new execut hire
busi develop activ jawbon etc realiz
rel spars mostli unpredict number compani expect acquir disappoint
investor believ return sector acquir realiz market capit
premium unlik return lower histor level given capit market fundament
start valu earlier stage compani environ think compani platform technolog
robust drug discoveri engin like acquir aspect poorli recogn
regulatori environ continu evolv provid expedit pathway disease-alt intervent
make sens one key driver perceiv willing regulatori
agenc expedit approv drug less data believ regulatori agenc appear
shift regiment view drug applic holist approach core shift
appear recognit understand scienc diseas becom robust
abil predict activ drug well-character regard regul includ fda
ema appear align shift taken invest commun regulatori flexibl shorten
path commerci increment lower development risk get
howev lower bar regulatori approv without consequ note previous
china becom signific opportun increas demand suppli current difficult
investor commun accur quantifi opportun china potenti largest market
world result number factor includ lack diseas epidemiolog rapid evolut
healthcar system concern exclus differ econom structur well access
chines clinician journal better understand current treatment paradigm anticip mani
factor like rapidli evolv chines compani becom nation compani china
begin adopt mirror aspect western system
see china signific compon world demand well produc viabl drug
candid demand novel drug like increas exponenti china infrastructur evolv
regulatori environ reimburs landscap matur also believ china
success gener novel drug especi given emphasi cultiv new technolog
intellectu properti well abil run clinic trial expedi rapid success
industri revolut china indic could see chines biotechnolog industri experi
stagger growth view hard see china becom one foremost produc
biolog given success manufactur durabl good
target agent continu use preferenti clinician broader intervent particular
relev coverag univers role target agent play treatment paradigm
especi relat broader treatment strategi like immuno-oncolog believ practic clinician
continu gravit toward target agent precis intervent rel immuno-oncolog
percept increas amount data suggest tumor driver mutat oncogen
respond well agent case actual worsen treat view
renaiss target oncolog continu evolv repres multipl invest opportun
oncolog stock recommend own
launch outperform stock oncolog sector seattl
genet loxo oncolog loxo beigen bgne tesaro tsro
better blueprint target oncolog page
develop highli select small molecul target tumor known driver oncogen
stock pressur loxo ret agent show earli data suggest potenti
efficaci wider therapeut window blueprint ret agent similarli investor also
becam concern anoth competitor deciphera may therapeut agent gist
drug would util ahead blueprint drug avapritinib think recent pullback unwarr
like short-liv present investor chanc one true market leader target
oncolog also note blueprint uniqu librari small molecul agent
believ repres uncaptur valu investor well integr futur drug discoveri effort
reach upper echelon driven adcetri emerg pipelin opportun page
believ experienc transform year despit commerci
biotech compani sinc adcetri initi approv compani show
commerci execut adcetri opportun time believ return like multi-
blockbust revenu driven unpreced adopt rate drug frontlin hodgkin patient
follow new subgroup analysi show adcetri produc absolut delta high bar
set standard care regimen expect compani continu deliv commerci
adcetri backbon well broaden revenu base emerg pipelin asset posit outcom
key binari event expect immin part invest thesi
loxo leader develop target oncolog agent demonstr unpreced
efficaci safeti clinic compani chosen diseas driver mutat well-
character target pathway highli select agent minim toxic
dose-optim three agent clinic near-term approv expect year post-ind
loxo repres superl combin scientif acumen regulatori savvi loxo implement
strategi understand tumor biolog leverag knowledg creat franchis product
address initi oncogen driver secondari mutat eventu develop
stock inexpens believ loxo deserv premium market leader
three prong invest thesi anchor btk option china page
beigen commerci stage biotechnolog compani number commerci drug licens
celgen market china well pipelin development asset lead pipelin asset
zanubrutinib differenti btk inhibitor develop b-cell malign target b-cell
pathway btk drug transform chronic lymphocyt leukemia cll diseas
patient die caus rather malign howev toler issu often result patient
stop therapi ibrutinib beigen zanubrutinib base earli data appear much
larger therapeut window fewer advers event see drug multi-blockbust asset beigen
also develop immuno-oncolog io agent tislelizumab antibodi purport benefit
maintain higher resist mechan allow tumor circumv blockad given
drug modifi fc region impact role macrophag resist third prong
beigen invest thesi deriv parp opportun gastric cancer one think
larg ignor investor follow disappoint class ovarian cancer well fail
lynpara trial gastric cancer drug subtherapeut dose still provid signal
activ also see evolv valu attribut potenti chines market demand beigen
forefront chines biotechnolog effort believ compani like signific home
ovarian cancer opportun provid backbon pipelin emerg page
tesaro commerci stage biotechnolog compani one market product zejula ovarian cancer
number pipelin drug current level think credit given potenti
expans zejula beyond ovarian cancer market emerg pipelin asset outperform
rate base belief parp class relev beyond ovarian cancer
pipelin begin emerg next month data present esmo octob
novemb april anticip
oncolog stock believ under-perform market
concern profil opportun beyond kit gist give us paus page
rate base input medacorp specialist drug profil especi
system mastocytosi pdgfra accord specialist blood level appear
suboptimum bind receptor import diseas drug appear induc self-metabol
certain level test clinic could becom import real world therapeut
window drug much import current attribut major market share
earlier stage kit gist premis could risk blueprint present strong data
gist expect immin current level think necessari forecast preferenti benefit
gist well attribut signific revenu sm think drug
oncolog stock believ perform in-lin market
uncertainti around european patent challeng keep us sidelin page
believ expand rubraca prostat cancer could add uniqu dimens clovi
invest thesi think stock like rang bound on-going patent challeng europ
resolv fundament impact neg decis europ debat especi regard
read-through composit patent expir believ remain
overhang given impact percept takeout option stock alreadi appear reflect
risk neg outcom oral hear schedul decemb
wait upsid emerg tazomatostat page
announc fda agre lift partial clinic hold tazematostat allow
trial resum enrol major chang protocol view signific
posit believ larg anticip opinion import resolut clinic
hold potenti unlock addit valu tazematostat outsid mutant fl patient erythroid
sarcoma tumor worth model await pathway forward wild type fl well earlier
stage diseas combin rituxan critic similarli pathway forward dlbcl
also reliant combin data yet present key lever clear prefer
sidelin
solid jakafi backbon await transform product emerg page
think perform line market transform opportun aris replac lost
ido opportun fail compani sever program could add valu like
gvhd program topic ruxolitinib cream see becom signific driver
stock addit data emerg fundament believ jakafi franchis worth
suggest minim valu attribut pipelin investor longer horizon could see
solid invest futur
compel scienc await visibl sever lever page
think agio success idh franchis well hematolog indic like pkd larg
assum current level result success idh launch sound scientif rational view
least one solid tumor program work see increment valu stori glioma
potenti largest commerci opportun think data thu far least compel
regulatori pathway could prolong given natur cours diseas addit data upcom
medic meet import strateg direct taken jacqualyn fous
assum ceo role februari
compani nametickerlp ratinglp price targetcurr stock px impli chang share price market cappeak lp enuespeak market capcash shareclin regulatori riskagio oncolog share price close
better blueprint oncolog initi outperform pt
bottom line initi coverag outperform rate
price target uniqu drug discoveri compani develop highli select oral
drug target driver number differ cancer molecular level compani intern
drug discoveri engin proprietari librari small molecul believ repres uncaptur valu
investor well increas strateg valu potenti acquir competit pressur
stock sinc march present opportun entri high overst
view expect key data updat applic market author compani
lead asset avapritinib view one leader target therapi oncolog
avapritinib use gist system mastocytosi repres valu
lead asset avapritinib highli select inhibitor tki kit pathway import
gastrointestin stromal tumor gist system mastocytosi sm drug demonstr
unpreced efficaci subset gist pdgfr potenti repres expedit regulatori
pathway given unmet medic need diseas importantli efficaci diseas also suggest
activ system mastocytosi attribut competit kit drug deciphera may share base
assess preclin clinic data suggest deciphera may reach
optimum level competit activ sm pdgfr see initi detail model
avapritinib commerci launch peak ww revenu across indic
competit threat overst view share march peak
primarili due competit concern gist sm deciphera well ret driven
malign loxo loxo op note believ deciphera similar
activ sm given profil drug lack compel data pdgfr homolog
bind site think earli determin commerci dynam gist addit data esmo
european societi medic oncolog may provid better insight competit
natur gist opportun avapritinib seem viabl therapeut window
translat better diseas activ regard ret malign see signific opportun
blueprint ret inhibitor even loxo continu show better efficaci expect major
lung cancer thyroid cancer mutat eventu progress subsequ therapi believ
favor updat loxo expect septemb world lung congress would view
result pressur share buy opportun
drug discoveri engin proprietari kinas librari repres uncaptur valu blueprint uniqu
compani use proprietari screen process identifi ind candid shorten time
introduc drug clinic reflect long ip runway key asset estim
without hatch-waxman extens addit proprietari librari tki molecul enhanc
uncaptur valu potenti acquir view believ clinic success
valid drug discoveri platform increas valu compani librari molecul capit
market typic poor visibl platform technolog drug discoveri engin repres
untap valu view
focus mutat drive tumor
initi op price target
favor entri point due overst competit pressur
target driver oncolog process drug discoveri compani
molecul clinic drug pend ind submiss compani focus molecular driver
oncolog process select small molecul aggress dose
select wide therapeut window potenti result better efficaci safeti patient
leverag highli select kinas drug previous undrugg diseas lead asset
avapritinib could commerci earli form gist mutat pdgfr diseas
current treatment option drug use treat gist includ gleevec sutent stivarga
shown activ patient mutat contrast avapritinib shown abil shrink
tumor mutat avapritinib breakthrough therapi design btd subgroup
nda file expect
avapritinib clinic data also suggest best-in-class profil treat system mastocytosi blueprint
produc compel clinic data avapritinib system mastocytosi diseas mark
accumul mast cell intern tissu organ limit treatment option avapritinib shown
high respons rate advanc sm orr evalu patient last updat eha june
well deep durabl reduct sever import marker bone marrow mast cell
level serum tryptas importantli deciphera compet drug also develop
gist sm shown limit efficaci pdgfr gist suggest may limit viabil sm
versu avapritinib overlap structur similar bind site
activ ret driven tumor develop tumor ret mutat
fusion pathway play import role lung thyroid cancer importantli data date show
drug highli activ lung cancer respons rate medullari thyroid cancer mtc
respons rate major patient remain drug patient updat
dataset expect late earli drug shown high respons rate
loxo compet ret drug also higher rate hypertens still think drug
use patient ret alter mani fail multipl line therapi lung cancer
think treatment paradigm anaplast lymphoma kinas epiderm growth factor receptor
egfr -posit tumor suggest similar treatment multipl line therapi dynam could occur ret
success liver cancer would repres upsid price target chosen
conserv model hepatocellular carcinoma given data date compani
partner drug greater china think data date least
compel clinic asset tradit extrem difficult diseas treat
given role liver drug metabol nutrit highli vascular natur organ
therefor chosen conserv estim signific risk adjust
probabl success program account valuat
favor entri point world lung septemb view pressur
competit concern loxo ret drug deciphera kit drug believ loxo decis
present addit ret data world lung congress month suggest compani
enthusiast updat result much impact could alreadi reflect share
possibl stock could experi volatil around oral data present numer data
updat expect see catalyst section would recommend buy share exit world lung
present septemb especi stock experi weak
catalyst includ addit gist data sm data regulatori pathway avapritinib
discuss catalyst section report see number upcom de-risk event
importantli updat avapritinib gist could occur fall either esmo connect
tissu oncolog societi provid initi data drug line data
import given investor concern deciphera could use preferenti line ahead
avapritinib year end like updat avapritinib data system mastocytosi could
provid better idea durabl respons diseas key driver revenu opportun
safeti toler also scrutin investor especi given specul drug may
use indol form diseas chosen minim current valu indol sm
model leav favor data upsid estim also expect updat
ret data given investor concern drug rel updat
import lastli believ gener conserv regulatori guidanc
anticip regulatori submiss pdgfr line gist updat avapritinib regulatori
pathway earlier line gist
controversi pressur share
vs ret driven tumor investor becom concern bpmc ret
agent like competit loxo ret agent given recent data
present agent see key catalyst section detail data present suggest
may superl activ given advanc patient treat
trial drug higher respons rate data date
potenti limit toxic grade hypertens patient could
suggest activ vegf pathway hypertens like burden clinician
treat cancer patient main relev impact therapeut window
view agre point appear activ cleaner opinion
also commun sever extern consult howev earli data small
number patient could chang updat hypertens could clinic relev
patient mani cancer agent side effect higher rate grade appear
manag lastli see target ret agent winner take situat drug
appear highli efficaci patient progress die diseas receiv multipl line
therapi given egfr paradigm lung cancer believ sequenti ret intervent
like commonplac even avail io agent view share extern consult
hypothesi etiolog resist futur data show sequenti ret inhibit activ
avapritinib vs deciphera gist anoth overhang competit
threat deciphera pan-kit agent concern fuel number
factor includ avapritinib perceiv select activ exon vs pan kit
activ well concern avapritinib therapeut window may wide initi thought
given cognit advers event anemia note recent present
view think difficult compar much clinic pre-clin data present
thu far agent term efficaci yet present activ line gist
deciphera activ overal respons rate includ line patient higher respons rate
key updat bpmc present line data whether usual oncolog tenet
less heavili pre-treat patient respond better intervent true avapritinib select activ
exon render less effect line regard think also difficult assess preclin
data present deciphera reli heavili assay test receptor affin
conflict result well limit knowledg diseas regard mutat evolut
burden extern specialist indic difficult link certain mutat burden anticip
activ line therapi phase clinic data critic
regard safeti therapeut window think avapritinib off-target
effect difficult point make clear assess given limit patient number
cognit effect note avapritinib hard assess medacorp specialist voic concern
side effect indic often seen chemotherapi similarli lipas
elev appear clinic relev base publicli avail data
efficaci phase trial critic determin true product profil
like benefit option return sector note macro section report
limit acquisit biotech sector notabl disappoint compani
perceiv target given bpmc rel near-term commerci oncolog asset uniqu drug discoveri
platform kinas librari think percept option like increas transact occur
especi similar oncolog asset
pt includ europ sale avapritinib pdgfr kit mutation-driven gist
avapritinib system mastocytosi sale hepatocellular carcinoma
revenu ret-driven malign non-smal cell lung cancer thyroid cancer valuat also
includ risk-adjust npv blueprint earli pipelin target drug discoveri
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current valu share us/eu avapritinib pdgfra avapritinib kit-driven avapritinib kit-driven avapritinib advanc system mastocytosi avapritinib indol system mastocytosi hepatocellular carcinoma ret-driven pipelin drug discoveri asset dilut share count risk-adjust equiti valu risk medicin avapritinib pdgfra gistus/eu avapritinib kit-driven gistus/eu avapritinib kit-driven gistus/eu avapritinib advanc system mastocytosi asm us/eu avapritinib indol system mastocytosi sm us/eu hepatocellular carcinoma us/eu ret-driven malignancyearli pipelin drug discoveri platform
exhibit blueprint medicin revenu forecast indic
avapritinib pdgfr gist anticip nda submiss avapritinib lead
commerci pdgfr subgroup model rapid uptak patient popul
current approv treatment option deciphera also develop tki
subgroup although limit clinic data seen date suggest less competit profil rel
avapritinib believ like releg use avapritinib failur data
begin show activ result peak revenu eu revenu given
compel clinic data seen date breakthrough therapi design btd assign
probabl success indic result risk-adjust npv per share repres
valuat
exhibit avapritinib pdgfr gist revenu estim
avapritinib kit-driven gist compani also studi patient kit mutation-driven
gist on-going phase studi respons patient kit-driven diseas appear less
impress pdgfr still promis view subset patient significantli larger
pdgfr approx incid subgroup also much competit
patient typic respond well novarti gleevec frontlin median month
approv second third line treatment includ sutent bayer stivarga deciphera also
develop kit-driven gist top-line data compani phase invictu trial
fourth-lin expect separ phase trial intrigu evalu treatment versu
sutent expect begin
base clinic data date potenti competit model kit-driven gist penetr
line therapi nda submiss avapritinib expect also seek acceler approv
gist potenti give avapritinib first mover advantag popul current approv
therapi base model higher initi penetr avapritinib rel
eventu split market share line beyond third line anticip posit
data blueprint phase voyag trial could drive approv late allow avapritinib
captur major share exist option stivarga second line model modest low
single-digit off-label use avapritinib ramp peak major share
second line go deciphera base result phase intrigu studi importantli expect
updat blueprint could chang market share fundament valu data compel
earlier line therapi
peak ww revenu estim respect avapritinib
contempl clinic regulatori risk separ assign probabl success higher
probabl success result total risk-adjust npv per share kit-driven gist
exhibit avapritinib ww kit-driven gist revenu forecast therapi
avapritinib system mastocytosi blueprint produc extrem compel data avapritinib
patient advanc system mastocytosi sm rare condit mast cell abnorm
increas result accumul within multipl organ eventu lead organ damag model
launch advanc sm eventu captur one-third patient result peak sale
 europ given strength data seen date assign
probabl success indic result risk-adjust npv per share
blueprint also explor develop avapritinib treatment indol form sm includ
smolder subtyp character patient two symptom higher risk
progress advanc sm model less valu indol form rel advanc sm assign
probabl success model peak penetr smolder subgroup
indol patient result combin europ peak sale repres per
share risk-adjust npv valuat
exhibit avapritinib ww system mastocytosi revenu forecast subtyp
ret-driven malign blueprint potent select inhibitor ret
kinas identifi oncolog driver thyroid cancer mtc well non-smal cell
lung cancer nsclc current phase initi clinic data present april
show promis respons rate lung thyroid cancer patient loxo oncolog also develop
ret inhibitor shown impress respons rate similar phase basket trial
initi data appear superl term efficaci safeti believ earli call
winner two ret inhibitor view space zero sum game potenti
treatment second line ret inhibitor treatment underappreci opportun view
model initi launch captur major
frontlin share lung thyroid cancer peak model captur
frontlin opportun repres revenu importantli see potenti
second-lin treatment ret inhibitor underappreci opportun patient fail
frontlin like receiv second line model assum
frontlin ret patient fail therapi eventu receiv treatment ret second line
opportun repres revenu approxim peak
ww revenu base clinic data date assign probabl success
repres per share risk-adjust npv valu
exhibit ww revenu forecast indic
exhibit ret inhibitor ww revenu forecast molecul
exhibit ret inhibitor revenu forecast therapi
hepatocellular carcinoma blueprint evalu select potent kinas
inhibitor target fibroblast growth factor receptor preliminari data suggest
promis activ patient biomark specif blueprint studi tki-
nave patient on-going phase trial intend initi trial combin checkpoint
inhibitor also note partnership announc june
develop blueprint drug greater china region includ plan submit ind
china health author enabl activ china clinic trial site on-going
phase trial tki nave patient well new clinic trial explor drug combin
cstone conserv model commerci peak eu sale
subgroup given difficulti develop drug well
safety/toler find earli data significantli risk-adjust opportun assign probabl
success result risk-adjust npv per share approxim
exhibit ww revenu forecast cirrhosi stage
earli pipelin drug discoveri platform core compon invest thesi base
compani drug discoveri engin strategi focus design kinas inhibitor target
cancer high unmet medic need key oncogen driver includ risk-adjust npv
per share account blueprint drug discoveri platform
exhibit risk-adjust valu program/ind
valuat methodolog use risk-adjust sum-of-the-part methodolog valu blueprint examin
clinic regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev revenues/expens use
wacc termin valu nopat indic depend length
patent protect account valu beyond add cash requir invest
risk valuat
clinic risk number on-going clinic trial develop candid
includ avapritinib trial produc clinic data disappoint rel
investor expect repres risk valuat
regulatori risk regulatori approv requir commerci prescript drug issu regul
result longer-than-anticip timelin failur gain approv blueprint drug would repres
risk current valuat
competit drug compet blueprint pipelin candid could produc superl clinic
data lead increas competit market less-than-anticip uptak bpmc product
repres risk current valuat
program catalyst
avapritinib gist blueprint lead compound avapritinib oral kinas inhibitor tki
potent select inhibit kit pdgfr avapritinib specif design inhibit overact
kit mutat implic variou tumor like gist activ mutat kinas activ loop
includ kit structur analog pdgfr mutat increas activ
kit-regul pathway lead increas cell prolifer actual mechan activ
thought destabil kinas inact state promot intern activ
loop dfg motif upstream mutat key element kinas activ pocket respons
posit atp phosphat transfer target protein lain et al plo comput biol jun
exhibit locat kit mutat relat kinas function motif
gastrointestin stromal tumor gist form soft tissu sarcoma deriv neuron tissu gi
tract tumor frequent harbor driver mutat kinas kit pdgfr although tumor
rel slow grow indol advanc case difficult control limit
effect treatment option beyond frontlin gleevec imatinib exampl respons rate frontlin
gleevec treatment median patient diseas progress relaps
markedli diminish benefit subsequ agent includ sutent sunitinib orr mpf
stivarga regorafenib orr mpf diseas progress character increas
mutat burden caus resist current avail tki
mutat patient kit driven gist mutat recogn resist mechan
gleevec gleevec bind within kit atp pocket kinas inact form dfg prevent
activ mutat caus constitut activ reduc avail gleevec
bind pocket reduc efficaci drug common primari driver mutat patient
variant gist known pdgfr gist render patient insensit gleevec treatment
importantli kit pdgfr structur homolog mutat activ
site mutat kinas similar suggest activ drug similar affin
target current avail treatment patient pdgfr gist gleevec
impact tumor progress diseas avapritinib origin design treat resist
primari refractori popul howev develop program expand earlier
paradigm kit driven patient light evolv knowledg mutat driver gist
molecul activ kit mutat
exhibit avapritinib potent select inhibitor activ loop mutant kit
pdgfr gist avapritinib studi pdgfr gist cohort phase navig trial
last updat annual meet connect tissu oncolog societi novemb
orr stood impress central review patient evidenc tumor shrinkag
median yet reach howev pdgfr gist patient respond
current therapi mpf approv agent fda grant breakthrough therapi
design btd avapritinib pdgfr gist blueprint intend file acceler approv base
updat phase dataset compani intend includ data kit gist patient
file
exhibit avapritinib activ pdgfr gist
kit gist avapritinib activ kit gist last updat cto heavili pre-treat cohort
patient dose qd phase ii dose qd pr
display tumor shrinkag month rate although nearli
activ pdgfr patient activ still compar favor current treatment option r/r kit
gist includ gleevec re-challeng report mpf
competit dynam type ii tki potent
inhibit kit pdgfr deciphera present updat data phase trial primarili
kit gist patient patient dose phase dose qd orr
line last avapritinib updat howev segment patient line therapi result
orr patient well excess publish benchmark sutent stivarga
exhibit activ gist
date deciphera shown limit data pdgfr patient dataset respons
howev activ kit gist caus pressur share percept dcc-
minimum peer competitor avapritinib patient addit data support
deciphera develop strategi move earlier line therapi contribut investor percept
avapritinib would releg later treatment set rel given broader kit activ
mutat
program catalyst blueprint intend updat data phase gist trial late
updat could possibl esmo octob novemb data previous
present base evolv knowledg gist progress blueprint expand navig trial
includ cohort kit gist patient first look data includ forthcom updat
blueprint suggest segment overal activ data line treatment provid relev
comparison data believ releas could improv investor sentiment demonstr
avapritinib activ competit earlier line therapi note deciphera updat phase
data set esmo possibl ahead blueprint present continu posit data could pressur
share ahead data releas follow
blueprint intend submit first nda avapritinib pdgfr gist kit gist deciphera
current run phase invictu trial kit gist data although expect
placebo control trial posit blueprint acceler file could make first market late line
blueprint plan pivot trial patient like begin design depend
upcom phase data subset compani contempl two potenti trial design includ
comer trial sutent compar possibl singl arm trial biomark select patient popul
deciphera intend run phase trial patient sutent enrol expect begin
believ blueprint trial meaning behind deciphera expect program
avapritinib sm system mastocytosi sm prolif disord mast cell rang
symptom sever commonli sm present indol varieti character primarili
elev potenti sever allerg reaction without impact life expect sm also
sever invas malign varieti includ aggress sm sm associ hematolog
malign sm-ahn mast cell leukemia mcl aggress varieti carri signific diseas
burden featur organ damag result mast cell infiltr find reduc surviv
current therapi sm rang symptomat manag anti-inflammatori anti-histamin
cytoreduct cladribin ifn- multikinas inhibitor includ rydapt midostaurin
primari oncogen driver sm kit rydapt activ well kit
mutat appear fold less potent avapritinib see rydapt approv
asm april strength patient singl arm trial gotlib et al engl
orr per modifi iwg-mrt-ecnm criteria trial
avapritinib phase asm trial last updat european hematolog associ eha annual
meet respons evalu treat patient unlik solid tumor assess main
criteria evalu avail follow scan order evalu per iwg criteria must
c-find organ damag attribut sm subgroup orr cr/crh pr patient
demonstr clinic benefit broad deep reduct serum tryptas marker mast cell activ
bone marrow mast cell reduct includ patient prior rydapt
exhibit avapritinib activ advanc system mastocytosi asm
program catalyst blueprint plan initi pivot phase trial asm pathfind
compani expect updat phase data american societi hematolog decemb
recal last year data featur plenari present base robust activ avapritinib
asm includ low dose blueprint intend pursu develop indol smolder
sm phase ii pioneer trial design support registr indic expect
begin trial design includ regulatori feedback program could catalyz share
indic repres potenti signific opportun due larg patient number potenti
extend durat dose howev larg upsid estim valuat
ascrib smolder sm given indol form sm associ invas diseas
primarili symptomat think bar regulatori commerci success high prefer
conserv opportun see data
ret alter malign blueprint potent select inhibitor ret kinas
identifi oncolog driver medullari papillari thyroid cancer mtc
small meaning subset nsclc ret form part receptor complex gdnf glial
deriv neurotroph factor famili ligand transduc signal cell signal ret
implic growth develop ret loss function associ kidney defect
hirschsprung diseas condit character lack gi tract innerv result intestin
misfunct damag
ret gain function abnorm includ varieti activ point mutat primari driver
mtc ret fusion predomin nsclc ret fusion aris chromosom
rearrang join wild type wt ret kinas domain togeth varieti partner fusion
partner contain structur motif enabl ligand independ dimer coil coil leucin
zipper dimer common activ step kinas caus self-phosphoryl chang
kinas domain activ conform ligand independ
exhibit ret signal pathway oncogen alter
sever older multikinas inhibitor mki activ ret cometriq cabozantinib caprelsa
vandetanib approv agent mtc exploratori analys pivot exam trial serv
basi cometriq approv mtc indic patient ret mutat respond better patient
without mutat sherman et al cancer dec provid valid ret
driver therapeut target similarli drilon colleagu found respons rate cabozantinib
small trial nsclc patient harbor ret fusion demonstr alter relev
although mki activ ret activ substanti lower level
drug intend target includ profil suggest limit therapeut window mki
target ret dose necessari effect ret inhibit like caus unaccept level toxic
primari target pathway design potent target ret spare
kinas common mediat tki tox
exhibit potent inhibitor wt mutant ret spare kinas
blueprint present first human data april evalu patient
achiev orr cr respons rate nsclc patient cr mtc
subgroup cr importantli activ mutat ret mtc wt ret fusion
nsclc although major hypertens signal
investor took indic potenti target activ
competit dynam specif ret inhibitor like design optim inhibit
ret without encount target tox kinas loxo present first patient
data compris two case report iaslc world lung congress follow
complet dataset
evalu patient ret fusion nsclc produc impress orr
confirm cr ret mutant mtc patient respond includ unconfirm
activ seen irrespect mutat type fusion partner start dose prior therapi
respons durabl patient remain therapi data cutoff
importantli appear clean toxic perspect treatment emerg
rise threshold major sever reach trial
data pressur share abstract releas confer
activ safeti profil drug remain impress view mani investor
consid superior ascrib major valu space loxo agre
profil present date superl term respons rate safeti howev
dont think enough data present call winner space dont believ
ret inhibitor space winner take base preced target patient popul lung
cancer fact major patient progress frontlin treatment see
second line ret inhibitor treatment signific opportun
program catalyst blueprint expect updat dataset late earli
believ compani could also articul detail potenti time design registr trial
recal loxo intend submit nda late present loxo plan
anoth updat data set iaslc world lung toronto septemb compani
indic present includ updat data patient present
addit month follow data cutoff juli vs april quick turnaround suggest
us anoth favor data disclosur like possibl deepen respons better sens
durabl respons believ data could pressur share investor await
follow-up believ favor announc loxo larg anticip would
recommend buy weak still see potenti compet space
companyprogram/drugtherapeut areaeventtimingev typetri phaseblueprint medicinesavapritinib system mastocytosisiniti phii pathfind trial patienth advanc initiationphiiblueprint medicinesavapritinib gastrointestin stromal tumorupd phi data kit pdgfr gist includ first look kit trial dataphiblueprint medicinespipelineundiscloseddisclos addit discoveri stromal tumoriniti phiii trial vs sutent initiationphiiiloxo driven malignancyupd data trial ret fusion nsclc iaslc world trial dataphiblueprint ossifican progressivapre-clin data asbmr medicinesavapritinib system mastocytosisupd phi data sm like trial stromal tumorupd data phi gist trial trial dataphiblueprint medicinesavapritinib system mastocytosisiniti phii pioneer trial indol smolder initiationphiiblueprint ossifican progressivasubmit ind fop driven malignancyupd phi data ret driven malign potenti disclosur registr pathslat trial dataphiblueprint medicinesavapritinib gastrointestin stromal tumorsubmit nda pdgfr kit gist mastocytosispotenti initi data trial dataphiblueprint medicinesavapritinib gastrointestin stromal tumoriniti pivot trial avapritinib kit initiationphiiblueprint carcinomaupd data phi trial includ biomark select patient trial stromal tumordata phi dose expans trial trial dataphiloxo driven malignancypotenti nda file ret driven malign base medicinesavapritinib gastrointestin stromal tumordata phiii voyag trial avapritinib vs stivarga kit trial dataphiii
mn except per share eu product sales- collabor total cogs- total oper oper incom total net incom incom tax expens benefit net incom convert prefer stock net incom common dilut basic share outstand dilut share outstand mm balanc sheet mn chang oper net invest financ equiti rais debt issuanc compani report leerink partner estim
reach upper echelon driven adcetri emerg pipelin opportun
bottom line initi coverag outperform rate
price target commerci stage biotechnolog compani one wholly-own
commerci asset adcetri number promis pipelin candid one top pick
given belief adcetri continu penetr frontlin hodgkin lymphoma hl indic
better anticip rate given key subgroup analysi pivot trial show
absolut delta versu prior standard care better origin present
believ impact subgroup analysi fulli reflect estim despit
compani post sequenti growth quarter addit bullish number pipelin
catalyst add increment valu year
secondari analysi expect drive valu unpreced adopt rate
origin data disappoint investor given initi absolut delta
investig arm standard care report less wall street anticip
consid commerci bar widespread adopt subsequ pre-specifi subgroup analysi
data north american cohort show much increas absolut delta magnitud
benefit believ like rapidli drive frontlin adopt especi nation comprehens
cancer network nccn guidelin revis believ subgroup analysi may genesi
elig frontlin candid estim may receiv drug full
quarter sale rapid rate adopt believ ultim drive penetr given
magnitud benefit messag clinician like hematologist
continu use legaci chemo regimen think eventu compel adopt adcetri
opportun may larger tangibl expect data immin
anticip data phase trial t-cell lymphoma immin believ
opportun may larger initi anticip well experienc rapid adopt given
dearth target agents/biolog indic standard care opportun
chemo regimen chop gener hematologist like rapidli adopt usag
especi commun practic may incentiv current asp averag sell
price reimburs set high degre confid posit trial
reason delin report
believ stori could expand beyond adcetri current attribut littl valu
beyond adcetri next anticip addit data enfortumab vedotin ev
metastat bladder cancer well small molecul highli select agent tucatanib breast
cancer colorect cancer check medacorp specialist suggest extrem high degre
enthusiasm ev bladder cancer exceed perceiv target fibroblast
growth factor receptor fgfr agent develop
commerci execut like continu pipelin emerg
initi op price target
still remain adcetri commerci execut stori thesi could broaden next
adcetri posit multi-blockbust drug lead commerci asset adcetri
antibody-drug conjug target antigen found surfac leukemia cell
molecul cytotox payload monomethyl auristatin mmae chemotherapi agent disrupt
mitosi adcetri approv relapsed/refractori hodgkin lymphoma patient sinc
opportun compani rapidli penetr captur major patient leerink estim
target patient popul recent approv use frontlin patient see adcetri
rapidli grow multi-blockbust statu driven robust advantag standard treatment well
favor commerci dynam incentiv clinician prescrib brand adcetri gener
chemotherapi potenti expans lymphoma forecast adcetri peak sale
absolut delta standard care drive adcetri growth adcetri approv fda
march use advanc hodgkin patient base data pivot trial call echelon-
first full quarter adcetri sale follow label expans
report adcetri sale increas qoq estim translat frontlin market
penetr elig patient base proprietari patient flow model quick ramp
initi quarter especi sinc label expans believ much success driven
recent updat absolut delta arm improv cure rate
standard therapi view compel clinician remind standard care abvd
adriamycin bleyomycin vinblastin dacarbazin chemotherapi cure rate make
high bar clear
forecast adcetri growth continu compani expand market messag nccn guidelin make
aavd standard care report data believ backbon adcetri revenu
like continu grow driven combin continu success indic
expans opportun peripher t-cell lymphoma addit market messag
drive uptak believ like clinician still use abvd chemotherapi
possibl nccn guidelin updat could make difficult justifi legaci treatment standard
expect posit data immin phase trial
test frontlin adcetri plu chemotherapi patient peripher t-cell lymphoma
believ trial report posit data base assess phase trial see
program catalyst section detail analysi descript view opportun
signific potenti ad revenu world-wide adcetri sale like expans believ
expans like robust uptak given lack targeted/biolog approv option
medacorp specialist enthusiast ev bladder cancer expect top-lin data
seattl genetics/astella enfortumab vedotin drug util sgen technolog
astella antibodi treat advanc bladder cancer patient fail io platinum chemotherapi
estim opportun could repres patient given high rate metastasi
patient diagnos earli fail surgic intervent medacorp specialist express
prefer agent versu target treatment like fgfr small molecul forecast ev
launch blockbust drug peak
tucatinib remain wild card sgen pipelin view conserv forecast
peak acquir cascadian pharmaceut advanc program tucatinib
highli select small molecul anticip data drug colorect cancer next
month breast cancer data drug purport attribut includ specif
potenc receptor less activ egfr receptor import improv toler
chosen conserv model drug see complet dataset
pt includ adcetri sale ex-us/canada royalti multipl line hodgkin lymphoma
consolid aethera set well second-lin off-label retreat multipl line off-label
pt also includ sale adcetri salcl ctcl alcanza set
indic well sale tucatinib breast cancer valu co-promot
astella enfortumab vedotin ev bladder cancer includ per share risk-adjust npv
robust earli clinic pre-clin pipelin drug discoveri engin well
risk-adjust npv antibodi drug conjug technolog collabor
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current value/shareadcetri r/r hodgkin lymphoma system alcl second line hl post-transpl hl hl retreat frontlin hl ctcl ex-us/ca breast vedotin ev bladder clinic pre-clin asset drug discoveryi ii collaborationsi ii asset count total risk-adjust equiti valu risk residu non-deplet profitabilityseattl genet inc r/r hodgkin lymphoma hl adcetri system alcl salcl adcetri second line hl off-label adcetri post-transpl hl aethera adcetri hl retreat off-label adcetri frontlin hl ctcl alcanza adcetri dlbcladcetri ex-us/ca royaltiestucatinib breast cancerenfortumab vedotin ev bladder cancerearli clinic pre-clin asset drug discoveryadc collaborationsresidu
exhibit adcetri revenu forecast driven frontlin uptak follow
adcetri frontlin hodgkin lymphoma seattl genet obtain approv adcetri
use stage iii/iv untreat hodgkin lymphoma patient march base result posit
trial studi adcetri plu chemotherapi current standard care chemo
regimen abvd result trial show approxim improv modifi progress free
surviv two year vs importantli pre-specifi subset analysi
north american patient trial present june show even
greater benefit key region given substanti benefit seen north american patient
believ adcetri like gain widespread adopt frontlin unlik clinician abl
dismiss magnitud delta prior standard care
date model suggest rel rapid uptak adcetri frontlin set penetr
approxim opportun first full quarter sale follow label expans
revenu exceed consensu expect expect strong uptak continu
base input medacorp specialist
view frontlin hl durabl revenu opportun limit competit like forese futur
given extrem high clinic bar set adcetri trial model rel rapid
penetr advanc stage iii/iv frontlin opportun model suggest penetr
may attain first full quarter sale follow label expans expect adcetri
becom entrench standard care frontlin treatment advanc patient model penetr
advanc patient opportun frontlin conserv model gradual low singl digit
percentag frontlin adcetri penetr frontlin treatment patient local diseas poor
prognosi penetr patient local diseas favor prognosi
believ intent run clinic trial earlier-stag hl patient believ
independ investig sponsor studi may produc data could potenti lead use
popul provid potenti upsid current forecast forecast peak sale
frontlin set repres per share npv model
adcetri addit hl line therapi adcetri establish mainstay treatment
hodgkin lymphoma patient progress beyond frontlin therapi detail hl model forecast
use subsequ line treatment includ second-lin third line post-transpl consolid
patient receiv retreat adcetri subsequ line therapi model total adcetri revenu
peak come later line use beyond frontlin specif see strong use
post-transpl consolid aethera set result peak revenu expect
retreat usag grow adcetri uptak frontlin set expand ultim result
revenu adcetri use hl beyond frontlin repres valuat
adcetri attribut per share risk-adjust npv sale adcetri
peripher t-cell lymphoma data expect phase trial label
expans anticip assum probabl success reflect assess
clinic data phase lead-in trial histor respons rate exist standard care
chemotherapi regimen chop cyclophosphamid doxorubicin vincristin prednison set
model rapid uptak diseas peak penetr result sale
adcetri ex-us/canada royalti takeda market adcetri outsid canada seattl
genet receiv royalti rang mid-teen mid-twenti percentag sale well sales-
base mileston model royalti rang probabl success account
residu risk current unapprov indic result estim per share risk-
enfortumab vedotin ev bladder cancer anticip top-lin data pivot phase trial
enfortumab vedotin ev treatment advanc bladder cancer patient fail checkpoint
inhibitor estim opportun could repres mani patient given
high rate metastasi patient diagnos earli progress follow surgic
intervent importantli medacorp specialist spoken express enthusiasm
antibodi approach target compar small molecul therapi inhibit fgfr
seattl genet develop ev co-develop collabor astella cost
profit share basi model moder penetr peak urotheli cancer
patient relaps follow chemotherapi checkpoint inhibitor result peak sale
ww sale assign probabl success base review
earlier clinic data result risk-adjust npv estim per share
tucatinib breast cancer obtain tucatinib via acquisit cascadian therapeut
casc drug highli select small molecul current pivot
trial current enrol patient breast cancer data program expect
data investig sponsor trial colorect cancer could provid proof concept
addit tumor type within next month conserv model penetr herceptin-tr
breast cancer patient commerci late line therapi start model
peak ww sale assign probabl success result per share risk-adjust npv
earli clinic preclin pipelin deep pipelin earli clinic preclin
molecul leverag compani proprietari technolog well sgen sugar-engin
antibodi sea technolog asset includ tisotumab vedotin tv develop genmab
target tissu factor cervic cancer solid tumor ladiratuzumab vedotin lv target
breast cancer develop treat advanc solid tumor auristatin
develop treat multipl myeloma among other assign risk-adjust npv earli clinic
preclin pipelin translat estim per share
collabor sever activ collabor
compani licens proprietari technolog exchang combin up-front payment
on-going licens revenu potenti mileston royalti base develop
commerci collabor includ number well-known larg pharma biotechnolog
compani mp roch genentech bayer glaxosmithklin well
compani develop target oncolog drug celldex progen assign risk-adjust
npv collabor technolog platform repres per share
exhibit risk-adjust valu program/ind
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun individu indic
region assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate cash flow
gener seattl genet asset determin total net present valu risk-adjust
asset total npv reflect remain clinic regulatori risk program
risk valuat
commerci risk competit compani develop treatment hodgkin lymphoma breast
clinic risk fail clinic trial compound develop includ adcetri
trial tucatinib enfortumab vedotin compani earli stage pipelin
regulatori risk fda reject seattl genet pipelin asset adcetri tucatinib enfortumab
vedotin compani earlier stage asset
program catalyst
adcetri frontlin hodgkin lymphoma adcetri approv treat stage iii/iv untreat hodgkin
lymphoma hl combin chemotherapi march approv repres
first major chang standard care patient decad approv base result
phase trial compar adcetri abvd hl highli curabl abvd
adriamycin bleyomycin vinblastin dacarbazin howev bleomycin long known present safeti
issu includ signific last pulmonari toxic damag elev treatment mortal
risk treatment mortal lifelong morbid particularli troubl frontlin hl popul
skew younger cancer longer life expect
prior dataset bleomycin toxic manag varieti method includ
shorten exposur bleomycin guid interim respons rathl pulmonari monitor sign
toxic method non-inferior standard howev typic lead numer declin
cure rate activ bleomycin reduc rational behind remov
risk bleomycin lung toxic simultan improv cure rate
primari endpoint modifi progress free surviv two year
tradit assess progress event includ diseas progress death also receipt
subsequ anti-canc therapi due incomplet respons frontlin therapi without actual diseas
progress modif intend accur assess cure rate theori measur
tradit follow therapi switch frontlin due residu diseas would bia result
succeed show signific benefit modifi adcetri contain regimen
two-year modifi independ review vs aavd vs abvd
importantli rate pulmonari toxic reduc adcetri arm studi death
control arm due pulmonari toxic wherea pulmonari mortal adcetri arm
death adcetri arm due neutropenia howev none patient treat g-csf
prophylaxi although trial succeed earli question clinician investor
magnitud benefit absolut benefit whether trade pulmonari tox sever neutropenia
worthwhil
pre-specifi analysi north american cohort pre-specifi subset analysi north american
patient present cohort consid import site
experienc dose manag adcetri toxic includ pragmat use g-csf granulocyt
coloni stimul factor neutropenia view subset analysi better repres expect
result domest commerci use also provid takeda data counter european hl treatment
paradigm often differ
key result analysi favor benefit standard care frontlin adcetri use
improv perceiv risk reward view physician investor north american patient two
year modifi assess independ review aavd arm
repres improv cure rate investig assess show larger benefit
adcetri improv modifi rate two year view hard delta
north american patient receiv adcetri experi higher rate neutropenia febril
neutropenia g-csf prophylaxi small subset substanti cut rate febril neutropenia
without prophylaxi g-csf
exhibit north american modifi independ review
believ enhanc activ seen north american patient repres signific advantag
adcetri vast major hematologist would unwil forgo despit prior experi expertis
administ abvd believ trial initi comer data releas provid strong argument
uptak despit consid modest improv cure rate given advantag avoid
bleomycin without decrement cure believ substanti improv cure north
american cohort combin benefit drop bleomycin compel like win
sceptic well see data key factor adcetriss larg sequenti growth like catalyz
adcetri frontlin peripher t-cell lymphoma next opportun adcetri
expans frontlin peripher t-cell lymphoma phase trial compar
adcetri plu truncat chemo regimen full standard care regimen newli diagnos
patient manag expect data earli agre fda modifi trial
design event driven analysi select time point unblind analyz believ
decis suggest compani confid magnitud benefit like seen
heterogen diseas compris sever type t-cell lymphoprolif disord
gener poor prognosi frequent present advanc symptomat diseas unlik b-cell
lymphoma chemoimmunotherapi becom part treatment paradigm outcom
patient gener inferior cell lymphoma patient possibl except system
anaplast larg cell lymphoma salcl alk better prognosi form salcl
benchmark low standard care chemo backbon chop cyclophosphamid
doxorubicin vincristin prednison core r-chop use b-cell lymphoma minu rituxan
respons therapi tend low rate deep remiss poor durabl one trial
newli diagnos patient achiev cr chop altern chemo chop produc
pr vs signific differ surviv chemo median
event free surviv ef month ef measur ef
month median os month arm simon et al british journal haematolog
adcetri marker activ lymphocyt seen varieti t-cell lymphoma
includ characterist alcl
phase trial chop seattl genet sponsor phase studi adcetri target newli
alreadi approv r/r form express peripher cutan t-cell lymphoma includ
alcl mycosi fungoid
phase trial enrol primarili salcl patient test two differ dose regimen first
sequenti dose two cycl adcetri follow cycl standard chop second regimen
combin approach adcetri administ chp vincristin omit cycl patient
respons end initi therapi elig receiv singl agent adcetri addit cycl
patient enrol receiv sequenti therapi respond follow cycl
adcetri cr pr howev patient progress chop portion
induct lead suspens trial arm patient enrol adcetri chp arm like
sequenti treatment patient subject object respons cr suggest robust
activ adcetri patient os estim patient
maintain cycl adcetri mainten one addit pr patient achiev
deeper respons convert cr
exhibit kaplan-mei curv phase adcetri trial
patient discontinu therapi due advers event ae although half occur
extend dose portion trial patient dose reduct primarili
mainten phase treatment relat death
recent follow-up data trial demonstr robust durabl adcetri treat patient
fanal et al blood may cr patient maintain respons
follow-up neither median os reach analysi event
observ patient month observ os estim
also note shape curv suggest year year respons appear
exhibit updat os curv adcetri chp
phase trial compar adcetri chp chop newli diagnos
primari endpoint trial assess independ review trial limit
enrol alcl known respons adcetri howev patient assess
oconnor et al journal clinic oncolog tp durabl respons
surviv seen phase trial highli impress although expect extend adcetri
treatment featur may contribut nonetheless except high
orr cr rate seen end induct therapi phase suggest respons high
expect translat advantag chop view also support
view earli patient experi standard chop abl maintain respons induc
adcetri patient suggest rel lower activ chemo patient
non-alcl patient also respond seven patient phase trial form ptcl
alcl patient achiev cr echelon ii seek enrol similar
proport non-alcl patient cap alcl enrol patient small number
assess chanc success non-alcl patient believ key trial
biomark select popul rather comer trial view reduc influenc
individu histolog rel proport enrol patient therefor
enrich adcetri sensit
non alcl group miss believ non-alcl patient respond trial
note phase trial patient alcl small indic pre-
specifi analysi differ subtyp would conduct alcl group
demonstr satisfactori efficaci regulatori agenc might consid abbrevi indic
revis label view outcom despit trial overtli posit would posit catalyst
stock especi given non-alcl group repres larger commerci opportun
sec file leerink partner estim
sec file leerink partner estim
scienc acumen regulatori savvi deserv premium initi loxo op pt
bottom line initi coverag loxo oncolog inc loxo outperform rate
price target loxo clinic stage biotechnolog compani develop oral drug target genet
driver tumor compani market leader target oncolog stock appreci
month septemb lead product path commerci
larotrectinib small molecul target trk-driven cancer heterogen basket malign
collect repres patient drug partner bayer fda decis
date novemb see primari valu driver stock contrast see loxo
rearrang transfect ret inhibitor repres major compani
valuat per share model
larotrectinib launch may challeng key lever tropomyosin receptor kinas trk
mutat low incid spread across number tumor believ uptak like
sluggish given treat clinician may transcend number specialti believ
ramp launch use proxi ret inhibitor target agent
like homogen think drug like approv novemb action date
result anticip given breakthrough design data program trk
franchis includ larotrectinib repres loxo valu model
ret agent perceiv best class key valu driver loxo model small
molecul target ret alter lung cancer thyroid cancer data date superl
term efficaci safeti drive loxo share sinc initi present world lung
congress septemb believ compet ret agent exhibit
similar efficaci profil drug like continu evolv dataset matur loxo
present updat ret data sept world lung expect data remain excel
given minor updat patient present month ago
believ add much fundament valu loxo share even stock react favor
headlin
think loxo deserv premium loxo pioneer target oncolog arena
initi drug gener superl data think justifi premium valuat believ
compani strategi own vertic focus therapeut area leverag compani core
compet develop precis small molecul make scientif sens small molecul
tyrosin kinas often tend develop point mutat driver mutat rather lose
deliv best class expect
initi op price target
continu see upsid stori
loxo perceiv best class develop small molecul see continu upsid
core asset advanc clinic assess major
compani valu deriv drug target ret alter lung cancer thyroid
cancer believ expect high agent domin market think market
underestim rapid drug use well adopt rate frontlin
medacorp specialist express desir use drug patient ret biomark
even initi label relapsed/refractori patient also believ compani btk agent
like use preferenti class drug patient develop btk mutat
prefer express medacorp specialist
loxo/bay trk inhibitor like approv record time loxo partner bayer like
larotrectinib approv fda action date novemb year first
patient dose drug demonstr superl data basket tumor includ lung breast
colon trk biomark collect patient us trial publish new
england journal medicin nejm show respons rate view favor regulatori
decis like view posit valid compani regulatori savvi despit larg
larotrectinib launch like challeng materi stori think trk
launch materi compani evalu current model gradual diagnosi rate treatment rate
trk patient given heterogen natur distribut tumor across differ specialti
contrast ret trk profil appear standard believ sluggish launch trk
proxi eventu ret launch much import loxo valu recogn
focu place trk launch given commerci asset loxo
could creat share volatil would expect tribul asset materi chang
investor percept compani import ret launch
next-gener trk inhibitor could add valu small opportun loxo also develop
next-gener trk agent intend address resist mutat larotrectinib
opinion excel strategi leverag compani compet infrastructur enlarg
trk opportun loxo report solvent front mutat note patient
success treat phase trial enrol next updat expect
besid ad valu trk opportun believ add compani perceiv expertis
develop fine tune target agent genet defin diseas
major valu driver compani target ret compound
develop collabor target ret derang loxo estim
annual incid rate patient us abnorm ret activ caus fusion
mutat lung thyroid tumor evalu patient ret lung cancer compani report
confirm respons rate similar efficaci albeit smaller number seen thyroid pancreat
tumor model attribut loxo valu ret agent give loxo major share
market
medacorp specialist suggest frontlin usag may occur frontlin approv believ
initi approv like refractori patient lung thyroid cancer drug
like get usag earlier line therapi given prefer among clinician treat driver
mutat theori also support medic literatur suggest patient driver
mutat respond agent also note label also carv patient
egfr mutat model assum frontlin usag start drug approv
refractori set acceler data avail frontlin approv
unlik trk mutat screen ret screen appear common mani facil especi
tertiari center given multi-kinas inhibitor target ret anticip ret
screen much bottleneck forecast trk
ret updat world lung expect favor loxo present data evalu lung cancer
patient thyroid cancer patient pancreat cancer patient june compani
present updat lung cancer cohort world lung septemb compani
indic investig group eager present data confer includ
updat cohort present possibl patient
evalu may ad analysi partial respons pr may
convert complet respons cr base waterfal plot present lung cancer
patient tumor shrinkag possibl cohort could yield cr
lung cancer cohort expect updat favor see littl fundament
upsid model alreadi incorpor best class
btk agent like use imbruvica progressor opportun estim
loxo develop revers btk inhibitor appear activ mutat provid
resist imbruvica irrevers btk inhibitor mutat mutat thought occur
patient progress imbruvica believ clinician like reserv usag
patient mutat add valu patient stop imbruvica toler safeti
issu leav upsid drug favor profil view clinician like tri
anoth irrevers btk agent patient discontinu imbruvica toler without
mutat see sizabl opportun loxo even though clinician may opt switch
class agent addit data on-going trial provid us detail better
understand dynam
risk-adjust sum-of-the-part deriv pt includ co-promot profit split trk larotrectinib
 royalti trk sale outsid sale
europ revenu ret-driven malign non-smal cell lung cancer thyroid cancer
us/europ revenu btk b-cell malign valuat also
includ risk-adjust npv loxo earli pipelin preclin asset
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current valu share us profit ret-driven b-cell pipelin preclin asset dilut share count risk-adjust equiti valu risk oncolog profit splitex-u royaltiesus/eu ret-driven malignancyus/eu b-cell malignancyearli pipelin preclin asset biotechnolog
exhibit loxo oncolog end market drug sale forecast row mn
larotrectinib trk-driven malign loxo oncolog lead molecul larotrectinib
activ potent pan-trk inhibitor given superl clinic data present date basket tumor
trk biomark expect fda approv novemb prescript drug user fee
act pdufa date novemb loxo sign develop commerci agreement
bayer larotrectinib next-gener trk inhibitor two compani co-
promot drug us bayer lead ex-u regulatori commerci activ loxo lead
global develop regulatori activ us deal includ up-front payment
loxo along elig receiv mileston payment upon regulatori approv first
commerci sale event certain major market outsid bayer commerci drug
loxo elig receiv tier doubl digit royalti net sale well potenti mileston total
incorpor mileston valuat loxo set receiv
mileston relat regulatori approv first commerci sale
view data present date compel see anticip approv launch
signific driver near-term valu loxo share given low singl digit preval trk fusion
across larg number tumor histolog see number commerci challeng temper launch
expect unlik sever well-known driver mutat egfr ret trk fusion appear
concentr specif tumor type pose challeng locat patient trk fusion
current avail diagnost also limit accuraci precis loxo activ work
develop deploy diagnost notabl implant trk test next-
gener sequenc platform compani believ help increas diagnosi
estim patient trk driver mutations/fus us midpoint current estim
rang model gradual increas diagnosi treatment rate trk
patient expect major patient identifi trk driver receiv larotrectinib model
penetr peak believ import valu lever program beyond diagnosi treatment
rate could price model start per month us co-
promot bayer control price market decis suggest final price may
loxo also develop next-gener trk inhibitor design address resist
mutat could emerg use larotrectinib limit visibl timelin clinic
program given small number trk patient date see strategi intellig way leverag
compani core expertis infrastructur maxim potenti trk opportun model
introduct conserv assum pariti price larotrectinib
model larotrectinib peak sale europ also note
trk program develop via research develop collabor array biopharma
arri rate origin sign array elig mileston payment
relat trk well mid-singl digit royalti sale model assign probabl
success larotrectinib europ result combin per share risk-adjust npv
exhibit larotrectinib sale forecast region
ret-driven malign select inhibitor ret kinas identifi
oncolog driver thyroid cancer mtc well non-smal cell lung cancer nsclc
loxo recent present data on-going phase portion basket trial
june show impress respons rate orr ret fusion mutant patent loxo guid
nda submiss potenti enabl approv commerci
similar larotrectinib discov collabor array biopharma compar
payment due array form potenti mileston payment mid-single-digit royalti
op also develop ret inhibitor initi clinic data
present april show promis respons rate lung thyroid cancer patient
initi data appear superl believ earli call winner
two ret inhibitor view space winner take potenti treatment
second line ret inhibitor treatment under-appreci opportun view
model initi launch captur major
frontlin share lung thyroid cancer peak repres revenu
also see potenti second line treatment ret inhibitor under-appreci opportun
patient fail frontlin like receiv second line model
assum frontlin ret patient fail therapi eventu receiv treatment ret
second line view meaning opportun revenu
also see increment opportun model revenu
base clinic data date assign probabl success repres
per share risk-adjust npv valu loxo
exhibit ww revenu forecast indic
exhibit ret inhibitor ww revenu forecast molecul
exhibit ret inhibitor revenu forecast drug therapi
b-cell malign oral revers btk inhibitor design
overcom resist mutat seen patient treat coval btk inhibitor
 js imbruvica loxo recent present preclin data societi hematolog oncolog
soho meet septemb describ bind kinet affin compani plan
submit ind initi phase clinic trial notabl unlik loxo advanc compound
larotrectinib acquir via purchas btk inhibitor program
redx pharma addit conting mileston royalti due molecul
clinic data yet molecul see market potenti meaning
loxo literatur suggest mutat occur mani patient progress
imbruvica believ clinician like reserv use patient mutat
unlik use broadli patient fail irrevers btk toler reason
believ physician may also choos switch class inhibitor venclexta rather
continu btk inhibitor design specif resist mutat await clinic data better
understand market dynam
model commerci prevalence-bas cll model suggest
address market frontlin btk progressor fail due resist
mutat well modest number patient progress btk inhibitor failur due
resist mutat model meaning penetr opportun peak penetr
result sale model penetr patient fail btk inhibitor
due toler issu remain seen whether viabl address market loxo-
penetr toler failur would repres upsid current estim assign
probabl success result risk-adjust npv per share loxo clinic data
compound need de-risk asset
earli pipelin preclin asset loxo oncolog also earli pipelin includ program
target cancer harbor fibroblast growth factor receptor fgfr mutat well recent form
intern drug discoveri group given earli stage develop model fgfr
addit drug discoveri opportun explicitli though includ risk-adjust npv
per share valuat
valuat methodolog use risk-adjust sum-of-the-part methodolog valu loxo oncolog
examin clinic regulatori commerci risk opportun individu indic
region assign probabl success account likelihood achiev revenues/
expens risk-adjust sum-of-the-part analysi appli discount rate cash flow gener
one loxo asset determin total net present valu risk-adjust asset total npv
reflect remain clinic regulatori risk program
risk valuat
regulatori risk commerci prescript drug requir regulatori approv loxo lead asset
larotrectinib fda decis pdufa date novemb larotrectinib fail obtain
approv date would repres risk current valuat also loxo pipelin
asset experi delay regulatori timelin rel investor expect would also repres
risk valuat
clinic risk loxo number on-going clinic trial develop candid includ
larotrectinib trial produc clinic data disappoint rel investor
expect repres risk valuat
competit drug compet loxo pipelin candid could produc superl clinic
data lead increas competit less-than-anticip uptak loxo product repres risk
current valuat
program catalyst
larotrectinib trk-driven cancer larotrectinib loxo lead agent potent specif pan-trk
inhibitor larotrectinib partner bayer bayer hold ex-u commerci right compani co-
promot drug us loxo respons global develop activ well regulatori
activ bayer lead ex-u regulatori activ world-wide commerci activ bayer pay
loxo tier doubl digit royalti ex-u sale loxo bayer co-develop us
cost profit split bayer ultim respons strateg financi decis includ price
within partnership loxo focus develop deploy trk diagnost partner
submit nda larotrectinib treat trk-driven tumor fda accept applic
prioriti review set pdufa date novemb submit august
mechan action trk famili tropomyosin receptor kinas receptor ligand
neutrophin famili trk signal involv growth prolifer neuron precursor
function develop nervou system trk fusion implic driver mutat
sever tumor although low frequenc rariti tumor larg number histolog
identifi present challeng accur assess trk fusion incid current
estim wide rang annual rariti trk fusion tumor present
clinic commerci challeng unlik ret fusion trk fusion appear concentr
tumor type limit experi treat physician find beyond technic
challeng design diagnost suffici accuraci ad hurdl chang practic
across sever tumor sub-specialti convinc doctor search tumor rare ever see
reason uptak trk test like requir wider use assay doctor run singl
panel test multipl rare driver lower perceiv cost test although loxo
engag work partner implement trk test platform work
unlik complet larotrectinib launch unsurprisingli loxo identifi diagnost develop
deploy focu bayer collabor key commerci level larotrectinib
exhibit trk fusion spread across multipl tumor type
larotrectinib test three phase i/ii trial includ phase trial adult advanc solid
tumor phase i/ii scout trial pediatr patient advanc solid tumor
phase ii navig basket trial includ adult adolesc patient
enrol patient popul contain wide rang age distinct tumor histolog
reinforc commerci challeng present target
larotrectinib produc impress activ patient popul confirm orr includ
cr includ patient pend respons confirm orr cr rate
importantli respons seen irrespect patient age tumor type trk gene fusion
partner respons highli durabl median durat respons mdor reach
updat remain on-going month median follow-up median progression-fre
surviv also reach median follow-up
respond patient overal remain therapi underw surgeri cur intent key
clinic outcom particularli patient sarcoma
exhibit larotrectinib anti-tumor activ trk fusion patient
competit dynam entrectinib multikinas inhibitor potent activ
fusion trk fusion origin develop ignyta asset acquir roch
ignyta acquisit entrectinib develop phase basket program includ two trial alka
entrectinib show robust respons patient fusion trial
impress respons rate durabl howev publicli avail data trial includ four
patient harbor trk fusion four patient respond therapi importantli respons
tumor agnost mirror activ shown larotrectinib entrectinib current studi phase ii
studi adult children trial basket trial enrol multipl tumor type open
patient trk fusion alter
although entrectinib appear activ trk fusion view major competit threat
larotrectinib data releas date larotrectinib far exceed current avail entrectinib
trk-driven tumor larotrectinib near regulatori decis entrectinib develop appear
focus fusion well-defin popul lung cancer far less emphasi enrol trk
patient addit see potenti toler risk entrectinib compar larotrectinib consid
higher rate dose interrupt reduct possibl result potent inhibit multipl kinas
program catalyst loxo recent present valid data trk diagnost work ventana
molecular analysi person therapi meet importantli first clinic updat
larotrectinib year given fall data nsclc trk patient present iaslc
world lung septemb esmo octob compani present updat nda
dataset present inform develop durabl toler drug
year addit matur dataset lastli pdufa larotrectinib nda novemb
ema applic review
ret alter malign loxo select inhibitor ret kinas
identifi oncolog driver medullari papillari thyroid cancer mtc
small meaning subset nsclc ret form part receptor complex gdnf glial
deriv neurotroph factor famili ligand transduc signal cell signal ret
implic growth develop ret loss function associ kidney defect
hirschsprung diseas condit character lack gi tract innerv result intestin
misfunct damag
ret gain function abnorm includ varieti activ point mutat primari driver
mtc ret fusion predomin nsclc ret fusion aris chromosom
rearrang join wild type ret kinas domain togeth varieti partner fusion partner
contain structur motif enabl ligand independ dimer coil coil leucin
zipper remain activ without normal control dimer common activ step kinas
caus self-phosphoryl chang kinas domain activ conform ligand
independ dimer lead constitut rather regul activ unregul
activ lead abnorm cell prolifer cancer
exhibit ret signal pathway oncogen alter
sever older multikinas inhibitor mki activ ret cometriq cabozantinib caprelsa
vandetanib approv agent mtc exploratori analys pivot exam trial serv
basi cometriq approv mtc indic patient ret mutat deriv benefit treatment
even perform better cometriq patient without mutat sherman et al cancer dec
provid valid ret driver therapeut target similarli drilon
colleagu found respons rate cabozantinib small trial nsclc patient harbor ret
fusion demonstr alter relev diseas target lancet oncol
although mki activ ret activ substanti lower level
drug intend target includ profil suggest limit therapeut window mki
target ret dose necessari effect ret inhibit like caus unaccept level toxic
primari target pathway design potent target ret spare
kinas common mediat tki tox receiv fda breakthrough therapi
design septemb loxo intend file nda drug like ret fusion lung
exhibit potent inhibitor wt mutant ret spare kinas
loxo present first patient data compris two case report iaslc world lung congress
follow complet dataset evalu patient ret fusion
nsclc produc impress orr confirm cr ret
activ seen irrespect mutat type fusion partner start dose prior therapi
respons durabl patient remain therapi data cutoff
exhibit treatment respons durat
importantli appear clean toxic perspect treatment emerg
advers event rise threshold major sever toler dose
reach trial
competit dynam chief competit blueprint molecul
also design maxim ret inhibit spare kinas particular blueprint
present first human data april evalu patient achiev
orr cr respons rate nsclc patient cr mtc subgroup
cr importantli activ mutat ret mtc wt ret fusion nsclc
major although event cross threshold
seen give overal impress less toler drug addit
hypertens signal investor took indic potenti off-target activ
signal seen cohort despit extens patient experi arguabl
sicker heavili treat patient popul signal caus investor commun
conclud cleaner activ caus major sentiment shift toward loxo least
far ret landscap concern
exhibit safeti toler
although concur profil date superior believ current
dynam immun revis medacorp specialist note impress toler seen
express reserv believ earli draw definit conclus
small sampl size repres model develop program far superl
respons rate safeti ret program remain earli stage given trend oncolog
believ remain possibl activ safeti profil erod well posit
updat could caus re-assess space importantli believ
commerci dynam suggest prefer among clinician treat tumor driver mutat
target agent immuno-oncolog io and/or chemo suggest opportun ret
inhibitor multipl line therapi hypothesi predic belief like
sequenti activ agent question answer knowledg learn
genet diseas evolut tumor resist
program catalyst loxo state intent submit nda late pend
complet pre-nda work mostli relat impress loxo plan anoth updat
dataset iaslc world lung quick turnaround suggest us anoth posit data disclosur
like possibl better sens durabl respons howev also note high expect
current level see limit fundament upsid loxo share favor updat
blueprint expect updat dataset late earli believ blueprint could also
articul detail potenti time design registr trial keenli focus
pathway frontlin regard compar arm need random trial well
anticip label could aris acceler pathway relaps patient
b-cell malign next-gener btk inhibitor design overcom
resist mutat seen patient treat imbruvica ibrutinib coval
inhibitor btk
btk bruton tyrosin kinas key part b-cell receptor bcr pathway essenti pathway b-
cell develop growth function activ btk also transduc signal activ
pathway includ toll-lik receptor tlr found immun cell play analog role btk
function elucid found mutat x-link agammaglobulinemia xla immuno-
defici condit character defect b-cell develop low concentr circul
antibodi first describ ogdon bruton central role btk bcr pathway
consequ regul b-cell growth surviv made natur target b-cell malign
imbruvica irrevers inhibitor btk form coval bond atp cleft kinas
activ site irrevers inhibitor tend potent classic revers inhibitor includ atp
competit molecul howev natur bind mode carri sever safeti liabil
therefor requir except specif use due concern imbruvica start tool
compound howev residu imbruvica coval bind fairli uniqu btk one
kinas known cystein residu atp cleft natur imbruvica interact
provid specif prolong time target enhanc btk inhibit also make
imbruvica highli suscept resist mutat common mutat point
substitut serin residu abrog imbruvica coval bind btk
significantli reduc potenc sinc mutat describ point substitut
next-gener btk inhibitor design maintain activ even btk
molecul employ revers bind mode depend number next-
gener btk advanc goal mind howev remain preclin
earli clinic develop difficult draw distinct among present
program catalyst loxo recent present preclin data describ bind kinet
affin societi hematolog oncolog compani plan initi phase trial
compani report leerink partner estim
loxo mn except per share revenu trk up-front milestones- royalties- co-promot us eu product sales- ret btk total revenue- cogs- relat parti total oper oper incom interest incom net incom incom tax expens benefit net incom dilut basic share outstand dilut share outstand mm biotechnolog
loxo bs/cf mn debt- chang oper net invest financ equiti rais debt issuanc retir compani report leerink partner estim
three prong invest thesi anchor btk option china initi
bottom line initi coverag beigen ltd bgne outperform rate
price target beigen commerci stage biotechnolog compani number commerci drug
licens celgen market china well pipelin development asset lead pipelin
asset zanubrutinib differenti btk inhibitor develop b-cell malign view
zanubrutinib multi-blockbust potenti ascrib valuat driven
favor efficaci safeti profil versu abbvi imbruvica also ascrib valu beigen
like captur signific market share china lastli think third prong thesi
pamiparib larg overlook investor option think valu develop western-
style biotech compani chines origin china like evolv investor gain confid tangibl
valu opportun
zanubrutinib appear highli differenti versu btk inhibitor btk inhibitor like
imbruvica ibrutinib chang treatment paradigm b-cell relat malign even displac
well-entrench drug like rituxan target b-cell pathway btk drug transform
chronic lymphocyt leukemia cll diseas patient die caus rather
malign howev toler issu often result patient stop therapi ibrutinib beigen
zanubrutinib base earli data appear much larger therapeut window driven better efficaci
favor pharmacokinet fewer advers event see drug multi-blockbust asset
even modest valu chines market importantli success develop asset could
continu valid beigen major biotechnolog compani creat halo effect futur opportun
drug tislelizumab may also differenti assum pariti agent beigen
also develop immuno-oncolog io agent tislelizumab antibodi purport benefit
maintain higher resist mechan allow tumor circumv blockad given
drug modifi fc region impact role macrophag resist see
opportun beigen china celgen collabor solid tumor malign outsid asia
assumpt modest base beigen get percentag forecast class revenu
product emerg differenti profil could upsid estim
parp opportun gastric cancer appear overlook follow fail lynparza phase trial
believ on-going phase pamiparib trial gastric cancer success read
could repres signific opportun beigen given preval cancer type asia
significantli risk-adjust opportun given fail phase trial astrazeneca note key differ
trial regard dose parp much lower given dose simultan
taxan chemotherapi potenti toxic unawar synergi parp
taxan think beigen mainten strategi platinum consist known profil
parp class howev note beigen trial biomark enrich repres risk
expect chines market becom tangibl investor ad valu bgne third
prong beigen invest thesi deriv evolv valu attribut chines market
demand beigen forefront chines biotechnolog effort believ posit
continu evolv pipelin success deliv commerci asset view celgen
drug gener signific fundament valu stock rel pipelin think commerci
execut start provid investor confid attribut valu chines market
three main asset option chines pharma industri
initi op price target
bullish beigen investor would like anchor fundament valu three promis
develop stage asset option evolv chines pharmaceut arena valuat
beigen btk inhibitor largest valu driver repres compani risk-adjust net
present valu geographi estim compani revenu origin china
fulli recogn potenti valu compani could eventu captur advanc
western-styl biotechnolog compani china help transform evolv industri
appear differenti earli clinic preclin data suggest drug potenti offer deeper
durabl respons imbruvica fewer side effect medacorp specialist suggest
signific opportun differenti btk agent could help expand class well improv
durat usag decreas discontinu current forecast revenu peak driven
primarili penetr leukemia cll lymphoma follicular lymphoma zanubrutinib phase
cll potenti acceler approv smaller indic mantl cell lymphoma mcl follow
anticip file us
attribut zanubrutunib drive differenti includ select better pk beigen
gener data show zanubrutunib similar plasma concentr imbruvica much lower
dose longer half-lif calquenc clinic data waldenstrom show deeper respons
zanubrutunib seen histor imbruvica well abil lower igm level
imbruvica deeper respons also seen zanubrutunib cll versu histor rate imbruvica
combin better potenc select creat wider therapeut window result
less toxic fewer discontinu histor seen imbruvica
beigen forecast drug china upsid driven product differenti
beigen believ tislelizumab also differenti agent deriv alter fc region
antibodi result less interact macrophag believ preserv durabl respons
conjunct celgen compani develop tislelizumab number solid tumor global
phase trial lung cancer nsclc liver cancer esophag cancer initi approv
expect china hodgkin lymphoma current forecast tislelizumab get portion
anticip revenu peak sale china row
pamiparib appear under-appreci current forecast beigen parp pamiparib
gener peak driven primarili penetr gastric cancer heavili risk-adjust
opportun think reason believ drug success patient atm- biomark
view drug appreci given focu beigen btk well
disappoint revenu tesaro clovi ovarian cancer market also think investor
larg dismiss gastric cancer opportun astra gold trial lynparza fail howev
see distinct reason could explain trial failur relat dose protocol on-going phase
trial gastric cancer success report data would expect bgne stock appreci
given size gastric cancer opportun china
chines pharma industri evolv think beigen well posit benefit number
reform chines healthcar system suggest opportun like rapidli evolv see section
chines healthcar believ chines compani like receiv preferenti treatment
govern agenc multi-national compani even physic presenc china
also believ chines govern continu incentiv compani foster innov
insid china view beigen uniqu posit first chines biotech ipo us offer
western-styl compani chines root signific catalyst bgne may first approv
drug us fda zanubrutunib file could valid compani ad
fundament valu
pt includ us europ china sale zanubrutinib btk inhibitor multipl lymphoma
leukemia indic includ cll fl mcl mzl wm sale teselizumab china
royalti celgen relat solid tumor sale outsid asia world-wide sale pamiparib parp
inhibitor gastric cancer china sale ovarian cancer well sale celgen product revlimid
abraxan vidaza avadomid china includ per share risk-adjust npv
beigen earli pipelin featur lifirafenib raf dimer well in-
licens sitravatinib mirati well compani drug discoveri platform
productpeak revenu mn phase developmentnpv bgne mn probabl successrisk-adjust npv mn expect launchnet current valu share us/eu zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk tislelizumab tislelizumab pamiparib parp pamiparib parp ovarian product china pipelin drug discoveri asset count risk-adjust equiti valu risk zanubrutinib btk cllchina zanubrutinib btk cllus/eu zanubrutinib btk mcl/mzl/wmchina zanubrutinib btk mcl/mzl/wmus/eu zanubrutinib btk flchina zanubrutinib btk flus/eu tislelizumab royaltieschina tislelizumab revenueww pamiparib parp gastricchina pamiparib parp ovarian cancercelgen product china collaborationearli pipelin drug discoveri platform
exhibit beigen ww end-us sale estim product
zanubrutinib cll beigen evalu zanubrutinib next-gener coval btk inhibitor
potenti differenti select half-lif rel current market btk inhibitor
abbvie/johnson johnson imbruvica astrazeneca calquenc see largest potenti driver
valu beigen revenu zanubrutinib use cll multi-billion dollar expand market
model cll opportun via uniqu prevalence-bas model rel indol
leukemia segment diseas line therapi use avail market compani data estim
number treat preval patient line therapi model contempl histor share trend
sinc estim market share follow class agent chemoimmunotherapi
btk inhibitor inhibitor inhibitor patient potenti receiv combin
therapi futur estim cll patient us receiv treatment
frontlin patient receiv treatment second subsequ line therapi
see zanubrutinib captur patient frontlin treatment second subsequ line therapi
non-btk progressor patient well patient fail frontlin btk inhibitor treatment due
toxicity/safeti concern peak model zanubrutinib captur new-to-therapi patient well
one-quart patient progress non-btk regimen unabl toler
btk frontlin result total revenu zanubrutinib cll model
peak revenu europ peak cll revenu china consid clinic
regulatori risk separ us/europ vs china base clinic data gener date assign
probabl success zanubrutinib us/europ region probabl success china
result risk-adjust npv per share per share us/eu china respect
approxim beigen valuat zanubrutinib across indic region compris
beigen npv
zanubrutinib follicular lymphoma beigen current studi zanubrutinib pivot phase trial
patient relapsed/refractori follicular lymphoma fl data anticip preliminari
combin data gazyva present show impress object respons rate
orr compar favor vs zanubrutinib gazyva monotherapi model us commerci
zanubrutinib r/r fl start gradual penetr second third line therapi
eventu captur third line opportun second line result net revenu
see european opportun china sale consid
clinic regulatori risk separ region assign probabl success us/eu
probabl success china total per share risk-adjust npv
zanubrutinib indic zanubrutinib also studi clinic program waldenstrom
macroglobulinemia wm mantl cell lymphoma mcl margin zone leukemia mzl beigen
studi zanubrutinib singl arm trial r/r wm patient phase trial data updat european
hematolog associ eha annual meet june show orr evalu patient
impress rate good partial respons vgpr compani plan submit nda
wm base data phase trial mark first potenti approv us beigen
also conduct phase trial wm head-to-head vs imbruvica treatment nave patient inelig
chemo data trial anticip
model us commerci start moder penetr wm follow subsequ
uptak mcl/mzl start model peak penetr rang us
european market result peak sale region addit driven
sale china peak given clinic data seen date assign probabl success
us/eu china result per share risk-adjust npv total opportun
exhibit ww zanubrutinib sale forecast indic
tislelizumab us/eu china tislelizumab antibodi beigen
develop conjunct celgen juli beigen enter licens agreement celgen
provid celgen exclus right develop commerci tislelizumab solid tumor us
europ japan rest world exclud asia exchang beigen receiv up-front
payment elig receiv double-digit royalti sale solid tumor celgen
tislelizumab studi global pivot phase trial nsclc liver cancer esophag
cancer well pivot phase r/r hepatocellular carcinoma us estim
patient treat agent rate treat patient grow faster
popul agent expand addit tumor types/lin therapi segment market
tumor type specif model use lung liver head neck cancer conserv penetr
tumor type result peak us sale see europ sale
peak lead us/eu total sale model tier royalti reach
assign probabl success opportun result risk-adjust npv per share
beigen strateg focu program china market featur larg number patient
sensit tumor two recent approv agent current avail
opdivo june keytruda juli anticip china market like
fragment mani domest option ultim becom avail view beigen run
three domest pivot trial lung cancer nsclc hodgkin lymphoma hl bladder cancer like
advantag domest term clinic program scope well suffici scale
commerci presenc model china market opportun estim incid
respons tumor grow annual approxim rate popul model
conserv penetr opportun tislelizumab eventu captur total market
treat patient beigen file approv china hodgkin lymphoma anticip
commerci domest begin assum price per month forecast
peak revenu china tislelizumab assign probabl success result
per share risk-adjust npv
pamiparib parp gastric cancer beigen conduct global phase trial pamiparib
mainten therapi platinum sensit gastric cancer opportun believ like
overlook investor follow failur astrazeneca phase gold trial lynparza treatment
detail analysi gold trial found report view gold trial provid
indic efficaci parp inhibit select patient believ beigen trial higher
chanc success base ration trial design dose regimen
anticip data read global phase trial potenti enabl launch
indic europ see strong uptak atm-neg patient
genet defin subgroup see greatest potenti pamiparib benefit see peak
penetr opportun result us/europ peak revenu china
anticip lower price per month similar penetr treat patient believ
atm-neg result pamiparib china revenu assign probabl
success program reflect assess level risk global phase trial
biomarker-select result risk-adjust npv per share valuat
pamiparib ovarian cancer domest beigen also conduct clinic trial third line
treatment set brca ovarian cancer patient well broader second line platinum sensit
mainten set see trial rel de-risk given success parp inhibitor
tesaro zejula astrazeneca lynparza clovi rubraca set model peak
revenu ovarian cancer china assign probabl success program result
per share risk-adjust npv
celgen product china connect tislelizumab collabor juli beigen obtain
exclus licens market celgen approv cancer therapi revlimid abraxan vidaza
china compani also acquir celgen commerci oper personnel china augment
beigen commerci infrastructur leverag market addit oncolog therapeut
either intern deriv in-licens although sale celgen product nearli doubl
aggreg sinc conserv model modest yoy growth go
forward given competit china see product signific driver valu
repres risk-adjust npv bgne asset encourag compani
meaning grow commerci presenc potenti leverag could provid in-licens addit
earli pipelin drug discoveri platform beigen deep pipelin proprietari molecul
includ lifirafenib raf dimer compani also in-
licens sitravatinib mirati explicitli model program believ
fundament valu beigen drug discoveri capabl infrastructur potenti make
compani partner choic biotech compani look commerci product china
includ per share risk-adjust npv bgne valuat
exhibit bgne risk-adjust npv per share program/ind
valuat methodolog use risk-adjust sum-of-the-part methodolog valu beigen examin
clinic regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev revenues/expens risk-
adjust sum-of-the-part analysi appli discount rate cash flow gener
beigen asset determin total net present valu risk-adjust asset total npv reflect
remain clinic regulatori risk program
risk valuat
clinic risk clinic trial failur beigen pipelin asset especi later stage drug includ
zanubrutinib tislelizumab pamiparib
commerci risk greater anticip competit either domest china intern could
impact perceiv valu beigen pipelin
regulatori risk failur obtain regulatori approv compani product unit state europ
china would like diminish valu beigen pipelin
program catalyst
zanubrutinib zabubrutinib next-gener btk inhibitor optim pk select
intend improv upon imbruvica ibrutinib respons avoid characterist
uptake-limit toxic market leader
btk bruton tyrosin kinas key part b-cell receptor bcr pathway essenti pathway b-
cell develop growth function activ btk also transduc signal activ
pathway includ toll-lik receptor tlr found immun cell play analog role btk
function elucid found mutat x-link agammaglobulinemia xla immuno-
defici condit character defect b-cell develop low concentr circul
antibodi first describ ogdon bruton central role btk bcr pathway
consequ regul b-cell growth surviv made natur target b-cell malign
imbruvica irrevers inhibitor btk form coval bond atp cleft kinas
activ site irrevers inhibitor tend potent classic revers inhibitor includ atp
competit molecul howev natur bind mode carri sever safeti liabil
therefor requir except specif use due concern imbruvica start tool
compound howev residu imbruvica coval bind fairli uniqu btk one
kinas known cystein residu atp cleft natur imbruvica interact
provid specif prolong time target enhanc btk inhibit also make
imbruvica highli suscept resist mutat common mutat point
substitut serin residu abrog imbruvica coval bind btk
significantli reduc potenc sinc mutat describ point substitut
imbruvica repres signific chang treatment mani b-cell lymphoma improv respons
surviv compar chemoimmunotherapi quit high case toler
oral regimen yet imbruvica signific toler issu well known report literatur
relat real world patient may discontinu treatment due toler issu within first
month brown blood characterist toxic imbruvica includ bleed
event rang minor petechia hemorrhag seen patient infect cardiac
side effect promin cardiac side effect seen imbruvica atrial fibril occur
patient earli treatment two year dose addit limit durat
therapi drug safeti concern preclud treatment patient certain risk factor off-target activ
believ contribut mani imbruvica side effect suggest possibl safer drug
still benefici attribut btk blockag addit btk imbruvica also found
inhibit egfr itk tec famili gener
sever next-gener btk agent vari stage develop approv agent
either sought address imbruvica resist mutat toler case zanubrutinib
potent btk inhibitor coval bind like imbruvica howev zanubrutinib higher
select btk expect translat better toler note zanubrutinib
potenc btk lower better suggest drug block receptor lower concentr less bind
off-target receptor higher better take higher concentr block receptor
exhibit zanubrutinib potent inhibit btk greater select imbruvica
zanubrutinib also appear prefer pk bioavail btk agent zanubrtinib achiev
compar system exposur imbruvica significantli lower dose longer half-lif
calquenc acalabrutinib importantli imbruvica calquenc show reduct btk occup
inhibit dose cycl may translat incomplet btk blockad sub-optimal activ
contrast zanubrutinib maintain higher consist level btk occup could drive
exhibit zanubrutinib pk/pd superior coval btk inhibitor
beigen studi zanubrutinib number b-cell lymphoma includ waldenstrom
macroglobulinemia wm chronic lymphocyt leukemia cll diffus larg b-cell lymphoma dlbcl
follicular lymphoma fl trial examin zanubrutinib singl agent combin
gazyva obinituzumab tislelizumab beigen
zanubrutinib wm waldenstrom macroglobulinemia indol lymphoma featur prolifer
lymphoplasmacytoid plasma cell elev level igm rais blood viscos beigen test
zanubrutinib singl arm trial r/r patient on-going phase head-to-head trial
imbruvica patient inelig chemoimmunotherapi primari endpoint cr
phase trial last updat european hematolog associ eha meet total
patient enrol trial evalu efficaci median follow-up orr
patient achiev vgpr contrast similar cohort treat imbruvica
orr vgpr higher rate vgpr seen zanubrutinib may contribut impress
high stabl progression-fre surviv seen patient
exhibit compel zanubrutinib activ wm
beigen current plan submit nda wm base phase trial data head-to-
head phase trial imbruvica expect
zanubrutinib cll chronic lymphocyt leukemia cll anoth indol heme malign involv
prolifer small matur lymphocyt cll cell found circul lymph node
bone marrow small lymphocyt leukemia sll consid condit cll
leukemia found circul
cll major market btk imbruvica approv wide use frontlin relaps
patient frontlin set imbruvica nccn categori recommend elderly/frail younger
patient comorbid relaps set imbruvica categori recommend patient
beigen current conduct phase trial treatment nave cll patient bendamustine/rituxan
br compar accept regimen patient suitabl fcr induct
fludarabin cyclophosphamid rituxan data expect beigen also run phase ii trial
r/r cll china plan global phase trial r/r cll vs imbruvica
earli data cll program zanubrutinib activ appear slightli seen imbruvica
data last updat intern confer malign lymphoma icml zanubrutinib post
orr cll patient includ cr treatment nave patient orr
r/r patient imbruvica orr cr r/r patient byrd et al new englj
orr cr treatment nave patient burger et al new englj
importantli plan head-to-head imbruvica expect primari endpoint trial would
surviv endpoint sensit overal therapeut profil includ
toler treatment discontinu preliminari data suggest favor zanubrutinib
zanubrutinib fl zanurbrutinib current studi pivot phase ii trial patient r/r
follicular lymphoma trial random patient receiv singl agent gazyva obinutuzumab
combin gazyva zanubrutinib primari endpoint trial orr durat
respons key secondari data trial expect
preliminari combo data present show impress orr cr
respons compar favor singl agent zanubrutinib gazyva well publish respons
imbruvica zydelig idelalisib similar popul
exhibit zanubrutinib gazyva show impress activ r/r fl
zanubrutinib toler key premis zanubrutinib valu proposit target btk
inhibit reduc off-target effect improv toler treatment complianc durat
importantli zanubrutinib appear develop differenti toler profil compar btk
patient mean exposur time rate atrial fibril major hemorrhag
respect substanti lower imbruvica addit patient longer follow-up
need better character incid event earli data promis
exhibit zanubrutinib display rate btk safeti risk
limit patient experi collect date zanubrutinib appear lower rate discontinu
includ toler mato ann oncol may colleagu publish real world
discontinu data imbruvica data initi publish cll patient treat
imbruvica r/r tn discontinu follow median follow-up due toler
due diseas progress frontlin patient treat imbruvica discontinu lower rate
due toler byrd ohio state group publish similar data calquenc
median follow-up calquenc patient discontinu due
due diseas progress
cll patient treat zanubrutinib treatment naiv r/r overal discontinu rate
patient follow median follow-up month one patient discontinu toler
richter transform rt natur dataset far smaller less matur avail
either imbruvica calquenc howev support thesi zanubrutinib potenti
differenti safeti toler profil may improv treatment durat complianc well
broaden potenti patient base
exhibit zanubrutinib discontinu rate lower competitor agent
tislelizumab tislelizumab antibodi beigen develop jointli
celgen beigen hold asia right solid tumor indic exclud japan world-wide right
heme malign beigen strateg focu program domest market china featur
larg popul patient sensit tumor howev market rel unpenetr opdivo
enter chines market june approv non-smal cell lung cancer nsclc keytruda
follow juli label melanoma beigen see earli stage market promis
opportun particularli given penchant chines consumers/physician prefer domest product
avail howev ultim believ chines market fragment
addit fact chines market remain open new agent enter beigen believ
tislelizumab may differenti key way may improv drug uptak key advantag
design featur tislelizumab fc modif reduc bind fc receptor fc mediat
antibodi direct cellular cytotox adcc immun process certain myeloid/antigen present
cell phagocytos antibodi bound cell case agent antibodi bind t-cell rather
tumor could result clearanc activ t-cell tumor abrog anti-tumor
effect similarli bind fc could re-establish immun suppress crosslink myeloid deriv
suppressor cell mdsc although modif strong rational improv activ earli data
program appear show activ yet differenti agent
therefor expect tislelizumab abl compet particularli chines market may
becom domin player market face grow competit
tislelizumab clinic program beigen studi tislelizumab global pivot phase trial nsclc
esophag cancer compani also run pivot phase ii r/r beigen
run three domest pivot trial tislelizumab phase trial non-squam nsclc phase ii
trial r/r hodgkin lymphoma bladder cancer trial hodgkin lymphoma basi
tislelizumab first nda china current review potenti approv late
tislelizumab activ agent yet proven differenti teslielizumab advanc dataset
phase ii cohort chines r/r hodgkin lymphoma patient recent updat top-lin data
trial show orr impress cr rate follow month follow-up hodgkin
lymphoma known activ therapi opdivo keytruda approv us
r/r set opdivo label orr cr rate popul fail stem cell
transplant adcetri brentuximab vedotin receiv median line therapi larger data
cut also includ patient treat adcetri opdivo orr
cr rate similar popul treat keytruda orr cr rate cr
rate achiev tislelizumab compar impress number prior line therapi transplant
experi access adcetri remain unknown would expect much higher respons patient prior
adcetri stem cell transplant
exhibit tislelizumab activ chl
initi data tislelizumab microsatellit instabl high msi-h mismatch repair defici dmmr solid
tumor chines societi clinic oncolog septemb evalu patient
msi-h/dmmr tumor colorect cancer respons orr three patient
evalu tumor neg msi-h/dmmr three progress diseas median
durat respons yet matur patient overal trial treatment month
median month median follow-up keytruda receiv first label msi-h/dmmr
tumor us total patient orr cr patient
respond treatment
beigen also report initi data tislelizumab chines patient two separ trial septemb
first trial enrol patient previous untreat local advanc metastat lung
cancer patient receiv tislelizumab plu platinum doublet progress
june data cutoff patient remain treatment object respons seen
evalu patient non-squam nsclc evalu patient squamou nsclc data
continu matur follow-up importantli consid manag revers
patient experienc least one grade consid possibl relat tislelizumab gener
see data mostli in-lin pembrolizmab grade interest immune-medi
report rate chemo-pembro combin arm
exhibit pembrolizumab interest
tislelizumab shown respons rang tumor demonstr broad activ howev data
avail date gener small cohort low number respons base data
evid tislelizumab activ howev conclud differenti activ
exhibit tislelizumab show activ rang tumor
pamiparib pamiparib inhibitor beigen develop beigen
conduct china-bas clinic trial platinum sensit ovarian cancer mainten gbrca
ovarian cancer treatment believ rel de-risk compani also conduct phase
trial platinum sensit gastric cancer mainten believ asset under-appreci
investor part due parp fatigu distract asset particular believ investor
may overlook opportun gastric cancer given fail phase trial azn lynparza
gold trial howev gold trial employ sub-optimal parp dose less use mainten
set patient popul treatment set question conjunct taxan
known parp synergi despit failur indic efficaci parp
inhibit select patient believ beigen trial higher chanc succeed base
rational trial design dose regimen although trial limit hrd-enrich patient
gold trial gold trial asian phase trial lynparza combin
paclitaxel vs paclitaxel gastric cancer patient primari endpoint trial overal surviv
os orr key secondari combin lynparza paclitaxel led numer
improv anti-tumor respons howev trial fail achiev signific endpoint
specifi signific level mo lynparza/paclitaxel treat patient compar
paclitaxel group ci atm- patient biomark expect
respond parp inhibit mo lynparza combo paclitaxel alon
ci similar result seen interestingli lynparza appear improv
orr particularli atm- subgroup vs outcom also fail reach
underdos lynparza patient gold trial receiv paclitaxel day
cycl addit patient receiv placebo tablet lynparza tablet bid dose
chosen improv toler combin chemo howev offer significantli lower drug
exposur approv lynparza dose bid possibl patient dose
effect rang lynparza lower parp dose may warrant gain combin synergist
activ chemo taxan microtubul inhibitor natur choic synerg parp
combo platinum reduc strength parp would make sens given platinum dna-damag
mechan parp mechan inhibit dna repair
wrong patient wrong set parp inhibitor studi activ treatment agent
mainten agent follow induct chemo trial studi activ treatment mean patient
relaps progress diseas almost exclus enrich parp activ typic enrol brca
mutant patient identifi homolog recombin defici hrd success
mainten trial enrol comer employ stratif enrol analysi identifi
respons relev patient subset addit mainten popul activ respons prior
chemo platinum provid enrich patient like parp respons
gold comer trial patient r/r gastric cancer patient respons
prior platinum difficult ascertain whether wild type patient parp sensit
stratif employ trial atm- patient relev hrd genotyp gastric
cancer enrich trial popul atm- patient trial popul line
popul preval wherea lead-in phase ii trial inform statist assumpt
patient atm- inde modest signal activ lynparza particularli
atm- orr howev magnitud benefit larg enough given statist assumpt
rel size cohort
read-through gold pamiparib light appar weak gold trial believ
mani investor write parp gastric cancer prematur importantli pamiparib trial
signific design advantag compar gold believ rais chanc success
pamiparib studi phase trial mainten agent frontlin gastric cancer
patient primari endpoint os key secondari trial compar pamiparib
monotherapi full clinic dose placebo contrast gold use paclitaxel monotherapi
activ compar random stratifi geographi ecog statu biomark statu
stratif biomark key enabl effect isol respons patient
broader cohort respond unlik gold patient relaps diseas patient
enrol mainten trial on-going respons frontlin platinum enrich trial
popul patient like parp sensit view maintain respons repres
lower clinic bar treat activ diseas
believ design choic rais chanc success pamiparib note parp mainten
trial sort highli success ovarian cancer remain risk atm mutat
less parp sensit brca mutat commonli found ovarian cancer howev believ
signal activ atm- patient gold signific benefit experienc brca wild type
hrd wild type patient ovarian cancer mainten trial suggest pamiparib activ
gastric cancer mainten agent data phase trial expect read
companyprogram/drugtherapeut areaeventtimingev typetri phasebeigenezanubrutinibchron lymphocyt leukemiainiti global phiii trial zanubrutinib vs imbruvica r/r initiationphiiibeigenezanubrutinibb cell lymphoma/cllupd phi monotherapi combo data trial dataphibeigenetislelizumabbladd cancercomplet enrol pivot phii trial chines urotheli carcinoma patient trial dataphiibeigenetislelizumabupd data china pivot trial dataphi/phiibeigenepamiparibmultipleupd phi singl agent combo trial solid tumorsiniti phi/ii trial advanc solid tumor initiationphi/iibeigenezanubrutinibchron lymphocyt leukemiainiti global phiii trial zanubrutinib vs imbruvica r/r initiationphiiibeigenezanubrutinibwaldenstrom scomplet enrol phiii trial zanubrutinib vs imbruvica r/r updatephiiibeigenecelgen portfoliocommerci updat celgen portfolio drug cell lymphomadata phii pivot trial zanubrutinib r/r mcl chines patient like ashdec trial dataphiibeigenetislelizumabhodgkin lymphomapotenti chines approv r/r hllate addit pivot trialslat initiationn/abeigenesitravatinibiniti phi combo studi tislelizumab chinal initiationphibeigenezanubrutinibwaldenstrom spotenti us nda file waldenstrom macroglobulinemia wm base global cell lymphomapotenti chines approv r/r phiii trial zanubrutinib vs imbruvica r/r trial dataphiiibeigenezanubrutinibchron lymphocyt leukemiadata phiii trial zanubrutinib vs br tn cll patient inelig trial dataphiiibeigenezanubrutinibfollicular lymphomadata phii pivot trial gazyva /- zanubrutinib r/r trial dataphiiibeigenepamiparibgastr cancerdata phiii mainten trial pamiparib platinum sensit gastric trial dataphiiibeigenepamiparibovarian cancerdata phiii mainten trial pamiparib platinum sensit ovarian cancer trial dataphiiibeigenetislelizumabesophag carcinomadata phiii trial tislelizumab vs physician choic chemo esophag trial dataphiiibeigenetislelizumabnon-smal cell lung cancerdata phiii trial tislelizumab vs docetaxel trial dataphiiibeigenetislelizumabhepatocellular carcinomadata phiii trial tislelizumab vs nexavar trial dataphiii
ovarian cancer opportun provid backbon pipelin emerg initi tsro
bottom line initi coverag tesaro tsro outperform rate
price target tesaro commerci stage biotechnolog compani one market
product zejula ovarian cancer number pipelin drug stock
signific pressur sinc feb drop high per share low
per share august relat disappoint zejula sale rel expect
percept fail transact investor unhappi level expenditur
pipelin yet gener signific valu date current level think
credit given potenti expans zejula beyond ovarian cancer market
emerg pipelin asset outperform rate base belief parp class
relev beyond ovarian cancer pipelin begin emerg
ovarian cancer market forecast repres fundament valu provid
solid backbon perform detail analysi ovarian cancer market opportun
base current anticip label zejula commerci parp use
conserv estim durat usag size opportun competit
dynam think overal ovarian cancer market peak tesaro zejula
captur market share translat given investor sentiment surround
stock believ forecast parp class ovarian cancer like move
tsro share view provid solid backbon investor wait pipelin
pipelin valu still opaqu expect visibl next month tesaro
number program pipelin receiv littl attent investor given
focu ovarian cancer market cash burn stock declin addit
expect lead sever data present disappoint investor result
littl pipelin valu ascrib tsro share next month believ
asset start emerg repres discret opportun well provid
synergi parp class key area lung cancer view emerg
pipelin reason invest tsro
data present esmo anticip octob esmo tesaro
present data garnet trial provid insight agent msi-h
endometri cancer could provid expedit pathway commerci
novemb data tesaro lung cancer solid tumor
present amber citrino garnet data phase
jasper trial lung test zejula plu present current model
direct revenu asset repres potenti upsid valuat
expect parp class pipelin repres
initi op price target
current level valu ascrib pipelin parp beyond ovarian cancer
tsro stock rel sustain free fall sinc peak per share feb
recogn neg investor sentiment may temper share price recoveri
base percept valuat alon believ pipelin start emerg
next month provid tangibl valu assess current
valu ascrib pipelin
capit market err one frustrat tsro investor
realiz valu zejula niraparib ovarian cancer peak zejula expect captur
signific major ovarian cancer market driven broad label endors usag
outsid brca patient statu short-liv astrazeneca lynparza grant
similar label clovi rubraca tesaro investor began realiz parp
alik differ toler differ agent medacorp
specialist indic differ led signific chang prescrib
three parp predominantli seen interchang similar also
contradict opinion express sever preclin meet american
associ cancer research led investor believ parp trap
phenomenon zejula advantag one born clinic
parp opportun ovarian cancer larg anticip expect parp
market ovarian cancer exceed billion driven promis prolong usag
drug mainten set high penetr rate would curb watch wait
approach paradigm diseas believ lofti assess ovarian cancer
market also valid larg pharma acquisit mediv merck
joint ventur deal lynparza believ real world experi parp result
less durat therapi anticip current model durat usag
line mainten set month also believ line set may
smaller opportun expect assess percentag elig line
mainten patient adopt parp mainten percentag
like peak base analysi input medacorp specialist
use conserv assumpt forecast peak zejula sale ovarian cancer
one aspect parp market dynam appear
underestim impact astrazeneca/merck broad label willing
clinician substitut parp peak current forecast astrazeneca/merck lynparza
captur ovarian cancer market tesaro zejula cloviss
rubraca given assumpt forecast ovarian cancer market collect
gener europ incorpor current anticip label chang
dataset assum penetr platinum resist insensit patient
could repres upsid estim lastli incorpor unexpect free
drug provis estim zejula rubraca lynparza demand
someth complet anticip launch
think investor ascrib valu zejula beyond ovarian cancer given
logist problem bravo trial lynparza signific head start think
mani investor given tesaro much valu breast cancer similarli given partner
program op think valu prostat cancer opportun
appreci also believ littl valu lung cancer given tsro
data begin emerg parp monotherapi well combin
expect opportun becom tangibl
data esmo tesaro could help elucid pathway toward
approv tesaro present data garnet trial
expect updat esmo drug msi-h endometri cancer
line trial view could form basi acceler pathway toward approv
final data garnet expect includ msi-h endometri cancer colorect
cancer mss endometri cancer note product approv
line mss endometri cancer merck keytruda label msi-h tumor
fail agent drug appear get usag area suggest commerci
opportun novemb addit data present
patient lung cancer non-smal cell lung cancer nsclc also clinic data
tesaro two molecul compani hope bolster activ
anticip tesaro continu temper expens could includ
partnering/divest asset revenu forecast zejula suggest current spend
level compani may need consid rais capit end therefor given
compani recent state reluct rais capit equiti level believ
consid partner and/or divest immuno-oncolog io asset could
provid non-equity-dilut fund well reduc expens level view could
help lift overhang stock although may also limit potenti valu pipelin
prima trial could give zejula differenti label import clovi ip success
rubraca salt patent novel oral hear schedul decemb
decis render see clovi initi detail medacorp specialist believ
possibl current patent narrow could open door challeng
invent step claim would also debat decemb decis could
minim impact europ rubraca regulatori exclus
orphan drug howev epo find camsyl salt lack novelti invent step
investor concern could increas gener parp could enter market
regulatori exclus beyond composit matter patent view
magnifi import on-going prima trial could give tesaro differenti
pt includ ex-u sale zejula multipl line ovarian cancer
treatment mainten therapi well valu niraparib use breast cancer
royalties/mileston base sale prostat cancer includ per share risk-
adjust npv niraparib use tumor type explicitli model includ lung
bladder pancreat cancer also includ risk-adjust npv
tesaro immune-oncolog pipelin includ
productpeak revenu mn phase developmentnpv tsro mn probabl successrisk-adjust npv mn expect launchnet current value/shareww zejula ovarian mainten zejula ovarian mainten zejula ovarian treatment zejula ovarian treatment zejula ovarian niraparib niraparib adjuv niraparib prostat tumor pipelin i/o asset share count total risk-adjust equiti valu risk non-deplet profitabilitytesaro inc zejula ovarian mainten ww zejula ovarian mainten prima ww zejula ovarian treatment quadra ww zejula ovarian treatment ava ww zejula ovarian retreatmentww niraparib mbcww niraparib adjuv bcww niraparib prostat cancerniraparib tumor typesearli pipelin i/o platform
exhibit ww zejula revenu forecast driven mainten ovarian
zejula second line mainten ovarian cancer tesaro obtain approv
march zejula use mainten therapi ovarian cancer patient achiev
partial complet respons platinum-bas chemotherapi base result phase
trial show signific progression-fre surviv benefit placebo
across patient regardless brca mutat hrd homolog recombin defici
statu detail ovarian cancer model see tesaro achiev maintain
approxim penetr avail second line mainten set line
peak share clovi rubraca slightli less astrazeneca lynparza peak
result forecast peak zejula revenu set anticip
occur prior cannib opportun expect parp use move
frontlin set set repres per share tsro valuat
zejula front mainten ovarian cancer prima tesaro conduct phase
prima trial zejula mainten therapi follow initi treatment platinum-bas
chemotherapi trial complet enrol data anticip late earli
posit top-lin data recent announc lynparza
phase trial evalu use frontlin mainten therapi patient germlin
brca mutat brca data expect present european societi
medic oncolog esmo annual meet octob anticip label expans
lynparza set anticip lynparza label restrict
brca patient studi trial believ tesaro prima trial enabl
broad label expans drive use patient without need genet test
model initi off-label use low single-digit percentag penetr set base
feedback medacorp specialist company-gener data suggest initi use
frontlin mainten therapi follow data late see zejula gain
moder uptak broad popul peak penetr non-brca patient
result forecast revenu zejula use set repres per
share npv model approxim tsro valuat
zejula treatment ovarian cancer data registr phase quadra trial
present american societi clinic oncolog annual meet
june show promis activ respons treatment brca non-brca patient
fourth later line tesaro intend submit snda zejula enabl potenti
label expans approv zejula would first parp inhibitor approv treat
activ diseas ovarian cancer patient regardless brca mutat statu model
approv peak sale reach increment assign probabl
success indic repres per share risk-adjust npv
tesaro also conduct phase avanova studi evalu zejula use without
avastin second line treatment set data trial expect potenti
lead uptak earlier line treatment chemotherapy-fre regimen avastin
see increment opportun model peak sale assign
probabl success result per share risk-adjust npv
parp retreat base feedback medacorp specialist also believ patient
receiv parp inhibitor one line therapi may receiv anoth parp inhibitor later
cours diseas especi context mainten therapi call parp
parp model parp retreat opportun increment opportun
provid single-digit percentag retreat penetr patient progress
follow parp mainten therapi either first second line result peak
zejula revenu result per share npv note establish parp
retreat standard practic could lead meaning upsid current forecast
niraparib metastat breast cancer adjuv breast cancer tesaro studi
niraparib genet defin subgroup metastat breast cancer gbrca
phase bravo trial howev compani initi intend trial registr
compani announc earli data unlik suitabl registr
due larg number patient drop control arm data expect
submit public although data unlik view lead label
expans anticip zejula see use metastat breast cancer set
valid parp inhibitor continu tumor type model peak sale
assign probabl success result risk-adjust npv per share
also model modest penetr parp brca adjuv breast cancer opportun
start follow read astrazeneca phase olympia trial
model major opportun share lynparza zejula captur
share peak result revenu opportun significantli risk-adjust
probabl success repres per share risk-adjust npv model
niraparib prostat cancer april tesaro enter collabor licens
agreement janssen biotech johnson johnson develop niraparib
prostat cancer term agreement tesaro receiv up-front elig
receiv addit clinic regulatori sale mileston well
tier double-digit royalti net sale niraparib prostat cancer respons
fund develop commerci expens indic model peak sale
niraparib prostat cancer result peak royalti tsro
risk-adjust opportun probabl success result risk-adjust npv
niraparib tumor type tsro i/o pipelin includ risk-adjust
npv per share account niraparib develop use tumor type
explicitli model believ like tumor type futur expans includ
platinum-bas chemo regimen histor play signific role lung
cancer bladder cancer colorect cancer also attribut risk-adjust npv
tesaro immuno-oncolog pipelin includ agent
explicitli model opportun asset believ
clinic data expect near term could enhanc visibl develop plan
timelin asset potenti lead greater investor interest fundament upsid
exhibit tsro risk-adjust npv per share program/ind
valuat methodolog use risk-adjust sum-of-the-part methodolog valu tesaro
examin clinic regulatori commerci risk opportun individu
indic region assign probabl success account likelihood
achiev revenues/expens risk-adjust sum-of-the-part analysi appli
discount rate cash flow gener tesaro asset determin total
net present valu risk-adjust asset total npv reflect remain clinic
regulatori risk program
expens financ previous note revenu forecast zejula suggest
current spend level annual split rel evenli sg
tesaro need consid rais capit end util method
gener fund current model equiti rais though anticip
compani consid partner and/or divest i/o asset could
provid non-dilut fund well reduc expens current level believ
non-dilut financ perhap collabor partnership could help lift overhang
risk valuat
commerci risk signific competit parp inhibitor class compet
drug includ astrazeneca/merck lynparza clovi rubraca development-stag parp
includ talazoparib veliparib beigen pamiparib competit lead
zejula revenu fail meet exceed expect repres risk pt
clinic risk fail clinic trial tesaro asset includ zejula
repres risk current tsro valuat
regulatori risk regulatori reject label expans zejula earlier line therapi
addit tumor type repres risk current tsro valuat
program catalyst
tesaro licens nr
tesaro view key pipelin strategi develop agent intend
compet larg pharma io program provid tesaro wholli own partner
zejula combin backbon next gen io combin therapi compani
believ field done cost effect greater oper
control flexibl partner establish agent commerci own agent
doublet therapi clear econom advantag addit potenti increment revenu
nich opportun could compet howev investor enthusiasm
asset mute suggest littl valu current ascrib
garnet trial phase dose escal studi test advanc solid tumor
enrol focus nsclc endometri cancer microsatellit stabl mss
microsatellit instabl high msi-h tumor includ endometri colorect other although
appear differenti base activ tesaro
implement uniqu dose schedul infus everi week steadi state oppos
common dose frequenc week
tesaro present preliminari monotherapi data relapsed/refractori r/r nsclc
r/r msi-h endometri cancer american associ cancer research
meet well toler safeti profil line pd-
agent seven percent patient grade higher treatment emerg advers event
nsclc patient achiev partial respons pr irrecist
respons seen irrespect statu msi-h endometri cancer object respons
rate orr assess irrecist
exhibit monotherapi activ nsclc garnet
exhibit activ msi-h endometri cancer garnet
tesaro updat data garnet msi-h endometri cancer esmo octob
nsclc novemb final data trial expect tesaro plan
submit initi biolog licens applic bla applic
includ msi-h cohort well parallel cohort mss endometri patient
seek approv patient irrespect statu current approv agent
mss endometri patient despit fact mss patient popul
repres attract earli market current valu opportun
explicitli leav upsid estim pend greater clariti activ
set specif await data mss endometri cancer well patient
number msi-h endometri cancer model opportun
tesaro initi registr phase trial vs standard high
nsclc result trial help determin registr path
monotherapi also influenc jasper program combin zejula
tesaro develop combin zejula mean
extend zejula activ within current new popul gynecolog tumor
phase first trial plan studi combin zejula
treatment mainten ovarian cancer trial follow tesaro prima trial
data late seek valid zejula mainten ovarian cancer patient
irrespect biomark statu first test addit standard platinum
doublet induct chemo follow mainten zejula control group
includ placebo control platinum doublet activ control platinum doublet follow
zejula mainten prima succeed placebo control arm first would
discontinu trial would still appropri compar arm trial plan
enrol patient data expect base clinicaltri gov
phase topacio trial studi combin zejula keytruda platinum-resist
ovarian cancer proc triple-neg breast cancer tnbc although data
program appear mix initi well receiv investor tesaro believ
earli work show import synergi two drug histor hard treat
patient compani plan continu work place keytruda
proc compani intend singl arm trial could enabl acceler approv tnbc
would requir compar phase trial howev exact popul enrol yet
phase jasper trial examin zejula new combin nsclc
trial enrol nsclc patient histolog arm base high low
tp tp trial also contain third arm enrol squamou nsclc
patient receiv zejula monotherapi tesaro recent present initi data trial
frontlin nsclc patient high treat zejula keytruda evalu
patient achiev object respons patient saw tumor shrinkag
data appear competit singl agent respons set
although show improv respons set
better singl agent patient high receiv singl
agent view earli jasper data provid valid
combin date howev note small patient number fact
respons confirm
base preliminari data tesaro open second stage jasper
addit patient enrol receiv zejula combin
replac keytruda initi data patient expect
exhibit activ zejula pembrolizumab nsclc
io combo beyond zejula combin also backbon two io combo
tesaro develop amber trial combin
initi data trial includ dose escal dose expans post nsclc
present first time novemb potenti meaning opportun
given promin lung high proport patient eventu relaps
addit follow-up trial expect
also initi monotherapi data agent advanc solid tumor
citrino also incorpor combin data expect
although earli trial key tesaro pipelin strategi import
understand potenti second tier checkpoint combin backbon
exhibit tesaro combin strategi gynecolog lung cancer
companyprogram/drugtherapeut areaeventtimingev typetri cancerpreliminari data phi garnet trial r/r msi-h endometri cancer trial dataphiclovi oncologyrubracaprost canceriniti data rubraca mcrpc present trial dataphiitesarolynparzaovarian data present like trial cell lung cancerupd data phi garnet trial nsclc trial cell lung cancerdata phi amber trial post nsclc trial solid tumorsdata phi citrino trial monotherapi advanc solid tumor trial dataphiclovi oncologyrubracaovarian cancercommerci rubraca updat on-going launch ovarian cancer mainten cancercommerci zejula updat on-going launch ovarian cancer mainten oncologyrubracaovarian cancer/bladd canceriniti phii basket trial rubraca opdivo brca- ovarian bladder initiationphiiclovi oncologyrubracaovarian cancerchmp decis expect rubraca ovarian cancer canceriniti phiii first trial treatment/mainten ovarian initiationphiiiclovi oncologyrubracaovarian cancerpotenti european approv rubraca ovarian cancer maintenanceearli cell lung canceriniti registr enabl phii trial vs soc high cell lung cancerupd data phi amber trial post trial cell lung canceriniti data phii jasper trial high trial dataphiiclovi oncologyrubracaprost cancerpotenti snda file rubraca brca mcrpc base solid tumorsupd data citrino trial includ combo trial dataphitesarozejulaovarian cancerdata phii avanova trial zejula/avastin r/r ovarian trial dataphiitesarozejulaovarian cancerdata phii ovario trial zejula/avastin ovarian cancer trial dataphiitesarozejulaprost cancerdata phi bediver trial janssen zejula/ar therapi mcrpc without trial cancer/nsclcfin data phi garnet trial msi-h endometri cancer r/r trial cancer/nsclcsubmit bla msi-h tumor includ endometri mss endometri cancerdata phiii prima trial zejula ovarian cancer maintenancel trial dataphiiitesarozejulaprost cancerdata phii galahad trial janssen zejula hrd mcrpc patient late trial dataphiiclovi oncologyrubracabladd cancerdata atla trial rubraca bladder cancerl trial dataphiiclovi oncologyrubracaprost cancerdata phii trial rubraca opdivo trial dataphiitesarozejulaovarian cancerpotenti snda file zejual ovarian cancer mainten base primamid oncologyrubracaprost cancerdata phiii trial rubraca vs physician choic ar therapy/chemo mcrpc brca trial dataphiiiclovi oncologyrubracaovarian cancerdata phiii athena studi rubraca/opdivo ovarian cancer trial dataphiii
tesaro inc incom statement million except per-shar revenu collabor expensescost in-process research oper incom incom tax expens net incom loss dilut ep share dilut share sourc leerink partner researchtsro bs/cf mm chang oper net invest financ equiti rais debt issuanc retir sourc leerink partner research
concern profil opportun beyond kit gist give us paus initi
bottom line initi coverag under-perform
rate price target deciphera clinic stage biotechnolog compani develop oral small
molecul treat tumor driver mutat compani lead asset pan-kit drug
develop variou malign includ gastrointestin stromal tumor gist system mastocytosi
sm drug shown promis efficaci kit-driven gist uncertain drug prove
efficaci opportun compani investig concern base medacorp
specialist view drug pharmacokinet dynam profil suggest limit therapeut window
blood level appear declin drug dose higher inabl reach level cell cultur
suggest optimum view current level believ investor expect
success system mastocytosi pdgfr platelet-deriv growth factor receptor alpha -driven gist
like avapritinib current assum use preferenti ahead
avapritinib gist possibl updat data blueprint could chang view
avapritinib appear better therapeut window even activ sm
pdgfr gist think unlik competit avapritinib
stock benefit valuat gap although see distinct differ
believ stock appreci sinc end may septemb
initi benefit comparison valuat also develop kit agent
gist sm howev see distinct differ avapritinib former
shown impress preclin inhibit kit mutat translat unpreced
clinic activ sm pdgfr gist preclin inhibit mutat fraction
seen avapritinib limit clinic data suggest drug may activ pdgfr gist
await sm data given preclin find limit activ pdgfr gist seen
date assign probabl success sm see opportun
domin earlier line kit gist could challeng appear less activ
specif mutat gist believ deciphera shown drug
pan-kit activ suggest drug may appropri earlier line usag avapritinib dcc-
shown respons rate second line third-lin patient exceed
respons rate seen approv therapi includ pfizer sutent bayer stivarga believ
earli definit design drug choic earlier gist especi given
evolut knowledg diseas process mutat burden howev model valuat
assum captur major line gist ahead avapritinib well
line repres peak revenu valuat per share risk-adjust
npv expect present data avapritinib second-lin set first time either
european societi medic oncolog esmo oct connect tissu oncolog societi
nov meet assumpt estim could risk
medacorp specialist voic concern pk/pd dose optim sm pdgfr gist
consult medacorp specialist regard publicli avail pk/pd data gaug
likelihood drug success beyond kit gist expert identifi concern blood level
activ metabolit declin dose increas suggest may induc self-
metabol addit specialist question whether drug could dose high enough
clinic effect sm pdgfr base publicli avail preclin data view signific
risk drug prove competit area rel blueprint avapritinib section
pk/pd pre-clin data make us paus detail
initi price target
narrow window bind profil concern
target driver oncolog process clinic stage
biotechnolog compani develop oral small molecul treat tumor gi tract brain solid
tumor compani lead asset develop gist system mastocytosi sm
brain tumor enter phase kit mutation-driven gist drug pan-kit activ
make well-suit use patient fail gleevec driver mutat kit pathway
shown impress data kit-driven gist patient fail gleevec
shown impress efficaci on-going phase trial gist patient line treatment
fail treatment gleevec gleevec ubiquit util treatment nave frontlin
set patient respond drug except certain subgroup howev
advanc gist tumor mutat eventu exhibit resist gleevec sever year
result tumor shown littl respons subsequ therapi low object respons rate orr
short durat respons seen current approv agent sutent stivarga
shown object respons rate on-going phase program patient impress
orr seen line patient line patient
pan-kit activ could provid advantag earlier gist patient fail gleevec
often exhibit multipl secondari point mutat exon variant shown
preclin clinic activ exceed seen commerci avail agent sutent
stivarga importantli also shown preclin activ literatur
suggest frequent secondari point mutat patient fail gleevec therefor kit-
driven gist model given major line refractori patient versu
avapritinib well nave patient line
data blueprint avapritinib second-lin set could challeng perceiv
advantag blueprint expect present line data phase trial refractori gist
first time avapritinib preclin data suggest target activ exon literatur
suggest patient refractori gleevec exhibit exon mutat fletcher et al pathol
activ exon although appear significantli less avapritinib
assay shown deciphera avapritinib shown aggreg respons rate patient
fail least two prior kinas inhibitor therapi third line later treatment line dcc-
respons rate includ line patient
therefor plan break-out earlier second-lin gist patient treat avapritinib particularli
import could help determin whether usual oncolog tenant patient less heavili treat
respond better subsequ therapi avapritinib narrow activ exon mutat render
less activ earlier line therapi rel former true would expect signific
pressur investor shift fundament valu earlier line therapi gist
preclin data suggest much less activ import pdgfr gist
sm base preclin data present deciphera avapritinib appear multipl time potent
mutat primari driver mutat pdgfr gist avapritinib
shown unpreced respons rate gist subtyp intervent
effect notabl patient show tumor shrinkag per latest updat novemb
similarli system mastocytosi case kit mutat avapritinib
show unpreced activ respons rate think difficult
competit sm pdgfr gist given preclin activ drug known driver
pharmacokinetic/pharmacodynam data suggest deciphera may troubl reach optimum
concentr sm pdgfr gist engag medacorp specialist review publicli avail data
base vitro data pk/pd data specialist question whether go forward dose
mg daili qd would abl reach optimum level impact receptor
import sm pdgfr gist addit expert note blood concentr
appear decreas dose higher suggest drug may induc self-metabol given limit
therapeut ceil level expert concern real world experi could result
sub-therapeut level sm pdgfr gist section pk/pd pre-clin data
make us paus detail
pipelin asset rebastinib could eventu add increment valu
concern fulli valu gist risk success sm deciphera addit
asset could eventu drive sharehold valu rebastinib inhibitor test breast
cancer chemotherapi also combin checkpoint inhibitor drug thought
import vascular growth well macrophag signal deciphera recent start global phase
trial solid tumor chemo similarli small molecul kinas inhibitor shown
preclin activ suggest abil help modul tumor associ macrophag
explicitli model opportun asset given earli stage develop
attribut risk-adjust valu per share compound continu monitor
progress clinic
catalyst includ updat gist data esmo octob initi sm data phase data
line gist anticip updat gist data phase trial present
esmo octob perhap meet blueprint could present initi data avapritinib line
gist occur simultan investor compar dataset physician percept
drug earlier line therapi addit possibl deciphera could present data
sm potenti provid first look efficaci indic importantli pivot data
phase invictu trial line gist expect investor focus
time dataset eventu commerci rel blueprint avapritinib nda file
gist expect blueprint suggest nda seek acceler approv
pdgfr gist well line gist treatment
pt includ europ sale kit mutation-driven gist well meaning
risk-adjust sale pdgfr gist system mastocytosi valuat also includ
risk-adjust npv deciphera earli clinic pre-clin pipelin includ rebastinib tie-
inhibitor solid tumor inhibitor solid tumor hematolog malign
phase trial
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current valu share us/eu pdgfra kit-driven kit-driven system clinic pre-clin pipelin asset share count risk-adjust equiti valu risk pdgfra gistus/eu kit-driven gistus/eu kit-driven gistus/eu system mastocytosisearli clinic pre-clin pipelin biotechnolog
exhibit deciphera pharmaceut revenu forecast indic
kit-driven gist deciphera studi patient kit mutation-driven gist
data phase invictu trial fourth-lin expect data on-going phase
trial evalu gist patient show encourag respons rate across multipl line
therapi includ second third line lead compani design phase intrigu trial vs pfizer
sutent expect begin also develop avapritinib kit-driven gist
acceler approv possibl fourth line later base expect nda submiss
base clinic data date potenti competit model avapritinib penetr
individu line therapi kit-driven gist kit-driven anticip could gain
initi approv base result invictu trial gist howev nda submiss
avapritinib expect seek acceler approv gist potenti provid first mover
advantag avapritinib popul current approv therapi base model lower
initi penetr rel avapritinib two agent eventu split market share
line beyond
much larger opportun deciphera view second line kit-driven gist
believ compani intrigu trial may lead label expans model uptak line begin
label expans could allow use earlier preferenti avapritinib
repres opportun europ model
third line blueprint phase voyag trial could drive label expans avapritinib late
allow drug captur major share exist option stivarga howev
anticip would also garner use patient receiv avapritinib
model approx peak penetr third-lin patient nave
peak ww revenu estim respect
contempl clinic regulatori risk separ assign probabl success higher
probabl success result total risk-adjust npv per share kit-driven
exhibit ww kit-driven gist revenu forecast therapi
pdgfr gist base limit clinic data gener date pdgfra patient
assess preclin data suggest blueprint avapritinib potent inhibitor
driver mutat pdgfra subgroup believ like releg second-lin
treatment patient mutat behind avapritinib limit patient popul us
incid patient year see pdgfr gist meaning opportun
model captur single-digit percentag frontlin pdgfr patient captur
major avapritinib failur subsequ line therapi result peak sale
subgroup given lack clinic data seen date preclin profil drug appear less
potent pdgfr mutat rel avapritinib assign probabl success
indic result risk-adjust npv per share
exhibit avapritinib pdgfr gist revenu forecast
system mastocytosi deciphera also evalu patient advanc
system mastocytosi sm clinic data present date comparison
preclin data vs blueprint avapritinib suggest less rel activ vs mutat key driver
sm case avapritinib demonstr impress respons rate on-going sm clinic
program suggest difficult compet first present clinic data
sm expect
given impress efficaci avapritinib demonstr clinic current major advanc sm
patient receiv avapritinib peak share vs also model low singl digit
penetr indol smolder diseas subtyp europ result peak
sale one quarter sale attribut avapritinib peak given lack
clinic data date assign probabl success result risk-adjust npv
exhibit ww system mastocytosi revenu forecast subtyp
valuat methodolog use risk-adjust sum-of-the-part methodolog valu deciphera examin
clinic regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev revenues/expens risk-
adjust sum-of-the-part analysi appli discount rate cash flow gener one
deciphera asset determin total net present valu risk-adjust asset total npv reflect
remain clinic regulatori risk program
exhibit risk-adjust valu program/ind
risk valuat
clinic risk could produc better-than-anticip clinic data result improv outlook
drug pdgfr gist system mastocytosi
competit drug compet includ avapritinib could
experi clinic regulatori commerci setback therebi improv prospect
acquisit believ unlik deciphera could acquir pharma biotechnolog
compani meaning premium would repres risk current rate pt
program catalyst
gist inhibitor multipl mutat kit pdgfr coverag
rang primari secondari mutat kinas activ profil deciphera
develop gist includ kit pdgfr driven varieti well sm
gastrointestin stromal tumor gist form soft tissu sarcoma deriv neuron tissu gi
tract tumor frequent harbor driver mutat kinas kit pdgfr although tumor
rel slow grow indol advanc case difficult control limit
effect treatment option beyond frontlin gleevec imatinib exampl respons rate frontlin
gleevec treatment median patient diseas progress relaps
markedli diminish benefit subsequ agent includ sutent sunitinib orr mpf
stivarga regorafenib orr mpf diseas progress character increas
mutat burden caus resist current avail tyrosin kinas inhibitor tki
patient kit-driven gist mutat recogn resist mechan gleevec
gleevec bind within kit adenosin triphosph atp pocket kinas inact form dfg
prevent activ mutat caus constitut activ reduc avail
gleevec bind pocket reduc efficaci drug common primari driver mutat
patient variant gist known pdgfr gist render patient insensit
gleevec treatment current avail treatment patient pdgfr gist gleevec
impact tumor progress diseas
pre-clin show greater potenc wt mutat kit sever common tki
includ approv agent gist gleevec sutent stivarga interestingli maintain
activ presenc primari mutat secondari mutat commonli caus drug
resist uniqu type ii inhibitor activ kit activ loop
mutat analog pdgfr mutat although less potenc form
kinas mutat consid resist gleevec archetyp type ii kinas
exhibit activ metabolit strongli inhibit primari secondari
mutat kit pdgfr
activ kit gist deciphera present updat data phase trial primarili kit
gist patient patient dose phase dose qd orr
howev segment patient line therapi result orr patient well
excess publish benchmark sutent stivarga suggest greater potenc
resist mutat could drive enhanc kit inhibit clinic benefit
exhibit activ gist
addit patient treat saw high rate diseas control outperform expect result
approv agent importantli diseas control object respons appear durabl
believ correl surviv gist includ late line patient
exhibit produc durabl respons diseas control gist
competit dynam avapritinib activ kit gist last updat heavili pre-
treat cohort line line patient dose qd phase ii dose
qd pr display tumor shrinkag month rate
activ compar favor current treatment option r/r kit gist includ gleevec re-
challeng report mpf orr line comer respons
seen unlik deciphera blueprint yet present patient data break-out
respons prior line therapi suggest avapritinib activ could also improv come updat
especi key oncolog tenet drug perform better less heavili pretreat cohort hold true
program catalyst blueprint intend updat data phase gist trial late
updat could possibl esmo octob novemb data previous
present base evolv knowledg gist progress blueprint expand navig trial
includ cohort kit gist patient first look data includ forthcom updat
blueprint suggest segment overal activ data line treatment provid relev
comparison data releas could caus volatil avapritinib show competit
activ earlier line therapi note deciphera updat phase data set esmo possibl ahead
blueprint present investor interest see orr maintain kind durabl
respons patient experi
futur develop deciphera intend run phase trial patient sutent enrol
expect begin blueprint plan pivot trial patient like begin
design depend upcom phase data subset believ blueprint trial
meaning behind deciphera expect program enrol robustli deciphera also on-going
phase trial compar placebo gist invictu trial wide expect
posit given activ seen date anticip report data blueprint
intend submit first nda avapritinib pdgfr gist kit gist acceler file
could make first market late line patient investor like remain highli focus
data time program given complet natur arena
activ loop mutat driver resist type ii inhibit gleevec kinas inhibitor bind
within atp pocket kinas inact bind mode class type ii inhibit type
inhibit drug bind activ kinas although gleevec potent inhibitor kit mani
relat kinas drug lose activ presenc mutat kinas activ loop
mutat relev form gist includ kit pdgfr system
mastocytosi harbor kit
activ loop mutat like driver increas activ kit-regul pathway
lead increas cell prolifer mechanist mutat thought destabil kinas
inact state promot intern dfg motif upstream mutat activ
loop dfg key element kinas activ pocket respons posit atp phosphat transfer
target protein lain et al plo comput biol jun thermodynam bia
toward activ conform reduc avail inact bind site type ii inhibitor need
activ
patient kit driven gist mutat recogn resist mechan gleevec
common primari driver mutat patient variant gist known pdgfr gist
render patient insensit gleevec treatment current avail treatment
patient form pdgfr gist
pk/pd pre-clin data make us paus
kit pdgfr analog share suscept kinas inhibitor amino
acid residu sm pdgfr analog locat locat respect
protein activ loop point mutat similar result term activ kinas
addit activ kinas mutat site preserv rel homolog kit
pdfgr activ site importantli kit pdgfr structur homolog
mutat activ site mutat kinas similar suggest activ drug similar
affin target appear case blueprint avapritinib shown robust
clinic activ patient pdgfr gist sm harbor kit
activ kit pdgfr activ
kit pdgfr base enzymat inhibit experi deciphera conduct
compar activ metabolit market inhibitor gleevec imatinib sutent
sunitinib stivarga regorafenib blueprint avapritinib exhibit below- note
data reproduc highlight activ differ target
metabolit sever order magnitud potent kit pdgfr
gleevec sutent stivarga smaller bar potent howev blueprint avapritinib
significantli potent target although difficult see given scale
axe avapritinib activ robust assay expect outcom given drug design
exhibit driver mutations- pdgfr highlight
exhibit driver mutations- kit highlight
cell studi suggest may enough potenc effect sm vitro
pharmacodynam experi confirm could inhibit prolifer cell line wt
kit howev significantli less potent cell line mutat
cell line wt kit line bear sensit mutat
wt kit nm compar nm cell line kit repres
drop potenc rosa cell wt kit nm kit line
fold loss potenc similar effect cell prolifer cell line wt kit like
becom apoptot treatment kit cell schneeweiss et al
exhibit inhibit cell prolifer less potent kit cell line
high dose inhibit primari mastocytosi line deciphera also test patient
deriv primari sm cell line cell repres clinic relev model cell line
prior experi activ cell presum harbor kit howev
robust activ achiev high dose drug dose human
sm cell nm also abl reduc histamin releas anti-ig
induc basophil dose depend fashion signific symptomat burden sm
resembl allerg condit caus releas allerg mediat histamin tryptas
howev prolifer sm cell line histamin reduct achiev high drug
concentr complet concentr nm reduc histamin
releas control level model rydapt midostaurin novarti approv agent sm
achiev greater reduct histamin concentr nm seen
concern although rydapt clinic activ kit remiss
achiev major patient suggest respons could limit clinic
exhibit high dose inhibit primari mastocytosi cell line
exhibit high dose inhibit histamin releas less potent rydapt
potent enough treat sm pdgfr gist order better understand
potenti sm pdgfr gist spoke medacorp specialist
pharmacokinet level drug exposur expect clinic set vitro assay
abl inhibit sm cell prolifer activ demonstr inhibit kit mutant
believ suggest analog activ pdgfr howev model
rang nm nm moder potenc call question clinic relev
activ normal drug high potenc target singl digit nm concentr
dose select pivot trial qd drug well toler dose escal
mg qd formal reach howev elev lipas level seen
bid bid compani character event transient
clinic meaning although deciphera believ report dlt signific believ
program limit capac use higher dose
pk curv suggest may reach therapeut effect level sm pdgfr pk
curv use estim much pharmacodynam effect might expect
qd dose plasma drug concentr qd
period estim nm convers assum concentr convers
nm publish deciphera
curv also note mg twice daili blood concentr lower seen
mg twice daili regimen medacorp specialist attribut possibl drug
might induc self-metabol could relev real world given patient like
multipl medic differ metabol profil
enough plasma level concentr estim may caus reduct
mast cell burden although would like less seen rydapt avapritinib
estim concentr impli littl inhibitori capac patient level variabl drug exposur
dose reductions/non-compli could meaning reduc activ addit supertherapeut dose
fail reach level histamin reduct achiev rydapt
bar sm rydapt approv advanc sm drug activ well kit
mutat appear fold less potent avapritinib rydapt approv asm
april strength patient singl arm trial gotlib et al engl
orr per modifi iwg-mrt-ecnm criteria trial
unlik competit sm avapritinib phase asm trial last updat european
hematolog associ eha annual meet respons evalu treat patient
unlik solid tumor assess main criteria evalu avail follow scan order
evalu per iwg criteria must c-find organ damag attribut sm subgroup
orr cr/crh pr patient demonstr clinic benefit broad deep reduct
serum tryptas marker mast cell activ bone marrow mast cell reduct includ patient
prior rydapt believ data set new bar sm one unclear meet
exhibit avapritinib activ advanc system mastocytosi asm
advanc sm deciphera test advanc sm patient part on-going
phase basket trial gener data kit pdgfr gist accord clinicaltri gov
trial start octob estim complet date decemb compani
indic hope present sm data howev believ investor share
skeptic program given clinic data releas date
pdgfr gist pdgfr gist form gist repres advanc
gist popul diseas mark mutat exon lack respons
commerci therapi includ gleevec repres tremend unmet medic need like
expedit regulatori pathway commerci
similar kit pdgfr mutant suggest similar pharmacolog inhibit
profil relationship support deciphera enzymat inhibit assay suggest equival
potenc target deciphera formal broken pdgfr cohort
phase trial poster highlight patient neither show tumor respons
exhibit activ pdgfr patient
given limit disclosur clinic data patient pdgfr gist lack respons
